
Title:  Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and 
Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to 
Severely Active Crohn’s Disease Who Achieved Clinical Response Following Open-Label 
Vedolizumab Intravenous Therapy
Study ID: [REMOVED]
Protocol Approve Date: [ADDRESS_89514] 2017
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information ([COMPANY_003]) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
1.[ADDRESS_89515] acebo -Controlled Study  to Eval uate the Efficacy  and 
Safety of Vedolizumab Subcutaneous as Maintenance Therapy  in Subjects Wit h Moderately to 
Severely  Active Crohn’s Disease Who Achieved Clinical Response Fol lowing Open -Label 
Vedolizumab Intravenous Therapy
Efficacy and Safety of Vedolizumab SC as Mainten ance Therapy in Crohn’s Disease
Sponsor: [COMPANY_005] Development Center Americas, Inc.
One [COMPANY_005] Parkway , Deerfield, IL [ADDRESS_89516], Nucl eos North Tower Level 4
Singapore, 138567
[COMPANY_005] Pharmaceutical Company  Limi ted, 
1-1, Doshomachi 4 -Chome, Chuo -ku Osaka 540 -8645, Japan
Study Numb er: MLN0002SC -3031
IND Number: [ADDRESS_89517] Number: 2015-000481-58
Compound: Vedolizumab SC
Date: [ADDRESS_89518] 2017 Amendment Number: 06
Amendment History : 
Date Amendment Number Amendment Type Region
[ADDRESS_89519] 2017 06 Substantial Global
Propert of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89520] Type/RoleAmericas, Europe, Asia and Japan 
TDC Contact 
[CONTACT_45300](medical advice on protocol and compound)
Responsible Medical Officer 
(carries overall responsibility for the conduct of the study)
Property of [COMPANY_005]: For non-commercialialall the applicable Terms of Usessigned signed
nt guidet guid
an he 
[COMPANY_003]
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89521] for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical trial disclosure laws, and regulations.
SIGNATURES
The signature [CONTACT_39842].Electronic Signatures may be found on the last page of this document.
bject to the applicable Terms of Usedadance nce 
wing:wing:
olidlidatedate
a privacyprivacy
e found ofound
cumcum
[COMPANY_003]
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89522] igator’s Brochure or
package insert as applicable, and any other product inform ation provided by [CONTACT_456]. I agree to 
conduct this study in accordance with the requirements of this protocol and also to protect the life, 
dignity, integrit y, confident iality of personal in formation, rights, safet y, privacy, and well -being of 
study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the Clinical Study  Site Agreement.
Appendix B–Responsibilit ies o f the Invest igator.
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Dof this protocol .
Signature [CONTACT_4235] (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Location of  Facilit y (Country )
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89523] 2017
1.3 Protocol Amendment 06Summary of Changes
Rationale for Amendment No.06
This document describes the changes in reference to the Protocol Incorporating Amendment 
No.06. 
The primary  reason for thi s amendment is to include a p re-Week 14 visit and to clarify the
Week 14 procedures for subjects who enroll and do not enroll into the open -label extensio n (OLE) 
study  (MLN0002SC -3030). Minor grammat ical, editorial, and formatting changes are included for 
clarificati on purposes only.
For specific descript ions of text changes and where the changes are located, see Appendix H. 
Changes in Amendment [ADDRESS_89524] ive and endpo int, and exploratory endpoint .
4.Clarificat ion to the Final Visit/Early Terminat ion procedures for subjects who complete (OLE 
Enroller/Nonenroller) at Week 14 (Induction Phase), a nd subjects who complete (Week 52) or 
discontinue fro m the Maintenance Phase.
5.Clarificat ion to the study design schemat ic.
6.Study  design updated to clarify  that all  endoscopi [INVESTIGATOR_82240].
7.Clarificat ion to Inclusio n Cri terion #11.
8.Clarificat ion to Excl usion Cri terion #5.
9.Clarificat ion to Exclusion Criterion #15.
10.Clarificat ion to Exclusion Criterion #20.
11.Clarificat ion to the period for excluded medicat ions and treatments.
12.Clarificat ion to Secti on 9.1.5 Vital Signs Proc edure.
13.Clarificat ion to Secti on [IP_ADDRESS] Diary Completion and Review.
14.ECG procedure updated.
15.Addit ion of a Pre –Week 14 visit for Week 6 nonresponders.
16.Update to
 Appendix ASchedule of Study  Procedures f or Crohn’s disease –related events.
17.Update to
 Appendix BResponsibilit ies of the Investigator.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89525] igator/Coordinating Invest igator ...................................................... [ADDRESS_89526] of Abbreviat ions............................................................................................... 16
3.4 Corporate Identificat ion........................................................................................... 18
3.5 Study  Definit ions..................................................................................................... 18
4.0 INTRODUCTION ......................................................................................................... 19
4.1 Background ............................................................................................................. 19
4.1.1 Diseases and Current Treatments ....................................................................... 19
4.1.2 Vedolizumab ...................................................................................................... 20
[IP_ADDRESS] Nonclinical ................................................................................................... 21
[IP_ADDRESS] Clinical Experience Wit h Vedo lizumab IV ................................................... 22
[IP_ADDRESS] Clinical Experience Wit h Vedo lizumab SC .................................................. 24
4.2 Rationale for the Proposed Study ............................................................................. 26
4.3 Benefit:Risk Assessme nt.......................................................................................... [ADDRESS_89527] ive(s) .......................................................................................... [ADDRESS_89528] ives......................................................................................... 28
5.1.3 Exploratory  Objectives ....................................................................................... 28
5.2 Endpoints ................................................................................................................. 29
5.2.1 Primary Endpo ints............................................................................................. 29
5.2.2 Secondary  Endpo ints.......................................................................................... 29
5.2.3 PRO Endpoints .................................................................................................. 29
5.2.4 Exploratory  Endpo ints....................................................................................... 30
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 32
6.1 Study  Design ........................................................................................................... 32
6.2 Justification for Study Design, Dose, and Endpoints ................................................ 36
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89529] 2017
6.3 Premature Termination or Suspension of Study or Investigational Site .....................38
6.3.1 Criteria for Pr emature Termination or Suspension of the Study ..........................38
6.3.2 Criteria for Prematu re Termination or Suspension of Investigational Sites .........38
6.3.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site(s) ................................................................38
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS ..............40
7.1 Inclusion Criteria .....................................................................................................407.2 Exclusion Criteria ....................................................................................................42
7.2.1 Gastrointestinal Exclu sion Criteria .....................................................................42
7.2.2 Infecti ous Disease Exclusion Criteria .................................................................43
7.2.3 General Exclusion  Criteria .................................................................................44
7.3 Excluded Medications and Treatments .....................................................................45
7.3.1 Permitted Medicatio ns and Tr eatments ...............................................................46
[IP_ADDRESS] Oral Corticosteroid Do sing and Tapering .....................................................[ADDRESS_89530] ......................................49
8.0 CLINICAL TRIAL MA TERIAL MANAGE MENT ......................................................50
8.1 Study Medication and Materials ...............................................................................50
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling .....................................50
[IP_ADDRESS] Vedolizumab for Injection, for Intrave nous Use (Vedo lizumab IV ) ..............50
[IP_ADDRESS] Vedolizumab Injection, for Subcutaneous Use (Vedolizumab SC) ................50
[IP_ADDRESS] Sponsor-Supplied Drug ................................................................................51
[IP_ADDRESS] Other Protocol-Speci fied Materials...............................................................[ADDRESS_89531] orage ..............................................................53
8.4 Investigational Drug Blind Maintenance and Unblinding .........................................53
8.5 Accountability and Destruction of Sponsor-Supplied Drugs .....................................54
9.0 STUDY PLAN ..............................................................................................................56
9.1 Study Proce dures .....................................................................................................56
9.1.1 Informed Consent Procedure ..............................................................................56
[IP_ADDRESS] ............................................56
[IP_ADDRESS] ...........................................56Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use388
........... [ADDRESS_89532] 2017
9.1.2 Demographics, Medical History, and Medication History  Proce dure..................56
9.1.3 Phys ical Examination Procedure ........................................................................57
9.1.4 Weight  and Height .............................................................................................57
9.1.5 Vital Sign P rocedure ..........................................................................................57
9.1.6 Primary Efficacy Measuremen t ..........................................................................57
[IP_ADDRESS] Diary Completion and Review......................................................................[ADDRESS_89533] ruments .............................................................64
[IP_ADDRESS] Inflammatory Bowel Diseas e Questionnaire ...........................................64
[IP_ADDRESS] EQ-5D Questionnaire .............................................................................64
[IP_ADDRESS] Work Productivity and Activity Impairment-CD .....................................[ADDRESS_89534] Tr eatment Comp liance..............................................................66
9.3 Schedule of Observation s and Proce dures ................................................................66
9.3.1 Screenin g ...........................................................................................................66
9.3.2 Enro llment/Rando mization .................................................................................66
[IP_ADDRESS] Nonresponders .............................................................................................[ADDRESS_89535] Study 6-month Long -Term Follow-Up  Surve y ...........................................68
9.3.6 Unscheduled Vi sits Due to Disease Exacerbation ...............................................68Property of [COMPANY_005]: For n mmercial use only and subject to the applicable Terms of Use5757
............[ADDRESS_89536] 2017
9.3.7 Poststudy Care ................................................................................................... 69
9.4 Biological Sample Retent ion and Destruction .......................................................... 69
10.0 PRETREATMENT EVENTS (PTE) ADVERSE EVENTS (AE) AND PRODUCT 
COMPLAINTS (PC) ..................................................................................................... [ADDRESS_89537] ion and Reporti ng of AEs........................................................................ 75
[IP_ADDRESS] PTE and AE Collection Period ............................................................... 75
[IP_ADDRESS] PTE and AE Reporting ........................................................................... 76
[IP_ADDRESS] Adverse Event Collection Involving Medicall y Anticipated Clinical 
Events .......................................................................................................... 77
[IP_ADDRESS] Speci al Interest AE Reporting .................................................................[ADDRESS_89538] ion Plan for PML (RAMP Program) ............................... [ADDRESS_89539] KEEPI[INVESTIGATOR_1645] ........................................................... 83
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89540] ions................................ 90
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 91
15.1 IRB and/or IEC Approval ........................................................................................ [ADDRESS_89541] OF IN -TEXT TABLES
Table 4.a Efficacy of Vedo lizumab IV in Subjects Wit h CD During the Induction Phase 
(Week 6, C13007) .............................................................................................. 22
Table 4.b Efficacy of Vedo lizumab IV in Subjects Wit h CD During the Maintenance 
Phase (Week 52, C13007) .................................................................................. 23
Table 7.a Eligibilit y for Study  MLN0002SC -3030 Based on Reason for Withdrawal ......... 49
Table 8.a Dose and Regimen ............................................................................................. 51
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89542] OF APPENDICES
Appendix A Schedule of Study Procedures: Screening, Induction and Nonresponders ...........[ADDRESS_89543] Informed Consent .......................................................108
Appendix D Investigator Consent to Use of Personal Information ........................................111
Appendix E ....................112Appendix F Crohn’s Disease Activity Index (CDAI) ...........................................................113
Appendix G ................................................114Appendix H Detailed Description of Amendments to Text ...................................................115
Property of [COMPANY_005]: For non-commercial use on d ject to the applicable Terms of Use................
NonrespNonre
............
...............
matatioionn
)..............
ments to enCCICCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89544] 2017
2.0 STUDY SUMMARY
Name [CONTACT_790](s):
[COMPANY_005] Development Center Americas, Inc. 
[COMPANY_005] Development Centre Europe, Ltd. 
[COMPANY_005] Development Center Asia, Pte. Ltd.[COMPANY_005] Pharmaceutical Company, Ltd.Compound:
Vedolizumab SC
Title of Protocol: A Phase 3 Randomized, Double-Blind, 
Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn’s Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous TherapyIND No.:
118980EudraCT No.:
2015-000481-58
Study Number: MLN0002SC-3031 Phase: 3
Study Design:
This is a pi[INVESTIGATOR_22735], phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled trial designed to 
evaluate the efficacy and safety of maintenance treatment with vedolizumab subcutaneous (vedolizumab SC) in adult subjects with moderately to severely active Crohn’s Disease (CD) who achieved a clinical response at Week 6 with open-label therapy with 300 mg vedolizumab intravenous (vedolizumab IV) at Weeks 0 and 2. 
Subjects that are either tumor necrosis factor-alpha (TNF- α) antagonist naïve or with TNF- α antagonist failure will be 
included, ensuring approximately 50% of subjects with TNF- α antagonist failure are enrolled. Subjects with previous 
use of TNF- α antagonist but not failed will be included ensuring th at no more than 10% of such subjects are enrolled.
Primary Objectives:
To assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week 52 in subjects with 
moderately to severely active CD who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0 and 2. 
Secondary Objectives: 
!To assess the effect of vedolizumab SC maintenance treatment on enhanced clinical response at Week 52 in 
subjects who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0 and 2.
!To assess the effect of vedolizumab SC maintenance treatment on corticosteroid-free remission at Week 52 in 
subjects who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0 and 2.
!To assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week [ADDRESS_89545] Exploratory Objectives:
!
Property o edExploraploreda: For non-commdolizumabolizum
clinical renical 
of vedolf ved
hieved clieved c
e effect oe effect
to TNFTN -mercial u y and subject to the applicable Terms of Usemsms
udraCTudraC
20152015 -0ab
ap
e:33th
lind, placlind, pl
mab subcuab subc
o achieveachieve
umab IV)mab IV
tagonist ngonist 
α antagoα antag
nsuring ing thto
intenancentenan
chieved clieved 
zumab IVumab me
ed
ytyCCICCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89546] Population: Adult subjects with CD, a ged 18 to 80 years inclusive.
Number of Subjects: 
Approximately 824 subjects enrolled to enable approximately 387 subjects 
to be randomized for maintenance treatment.Number of Sites: 
Approximately 240 sites globally
Dose Level(s):
Vedolizumab SC, 108 mg.
Vedolizumab IV, 300 mg.Routes of Administration:
Subcutaneous
Intravenous
Duration of Treatment:
52-week treatment periodPeriod of Evaluation:
The study  includes a 4-week (28-day )
Screening Period, a 6-week open -label 
vedolizumab IV Induction Phase,and a 
46-week randomized, double - blind, 
placebo -controlled Maintenance Phase 
with vedolizumab SC with a final visit 
at Week 52. 
Subjects who do not participate in the 
open -label extension (OLE) study will 
be required to participate in a Final 
Safety Visi t 18-week s after the last 
study drug dose and a long -term 
follow -up (LTFU) safety survey by 
[CONTACT_82261], [ADDRESS_89547] dose 
of study drug.
Main Criteria for Inclusion:
The subject has a diagnosis of CD established at least [ADDRESS_89548] has CD involvement of the ileum and/or colon, at a minimum .
The subject has demonstrated an inadequate resp onse to, loss of response to, or intolerance of at least 1 of the 
following agents: immunomodulators, corticosteroids, or TNF-α antago nists.
Main Criteria for Exclusion:
The subject has had extensive colonic resection, subtotal or total colectomy.
The subject has a history of >[ADDRESS_89549] has a positive progressive multifocal leukoencephalopathy (PML) subjective checklist at Screening (orat 
Week 0 before the administration of study drug ). 
The subject has received any investigational or appro ved biologic or biosimilar within [ADDRESS_89550] has had prior exposure to natalizumab, efalizumab , 
etrolizumab, AMG -181, anti -mucosal addressin c ell adhesion molecule -1(MAdCAM -1)antibodies, or rituximab.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89551] 2017
Main Criteria for Evaluation and Analyses:
The primary endpoint for this study is the proportion of subjects with clinical remission, defined as CDAI score ≤150, 
at Week 52.
Secondary endpoints for this study are:
!Proportion of subjects with enhanced clinical response, defined as a ≥100 point decrease in CDAI score from 
Baseline (Week 0), at Week 52.
!Proportion of subjects with corticosteroid-free remission, defined as subjects using oral corticosteroids at 
Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52.
!Proportion of TNF- α antagonist naïve subjects who achieved clinical remission, defined as CDAI score ≤150, at 
Week 52.
Select exploratory end points for this study:
Statistical Considerations:
All statistical testing will be performed at 2-sided 0.[ADDRESS_89552] secondary endpoint is statistically significant. 
All dichotomous efficacy endpoints will be analyzed using Cochran-Mantel-Haenszel tests for risk differences, 
stratified by [CONTACT_35876]. All subjects with missing data for determination of endpoint status will be 
considered as a nonresponder in the analysis. 
Sample Size Justification: 
Assuming a clinical remission rate of 38% for vedolizumab and 22% for placebo at Week 52, a sample size of 
258 subjects in the vedolizumab SC group and 129 subjects in the placebo group will provide 90% power at 2-sided 0.05 level of significance. To ensure a randomized sample size of 387 subjects, assuming 47% of the subjects entering induction will ach ieve clinical response at Week 6, approximately 824 subjects will need to be enrolled into the study.
Property of [COMPANY_005]: For non-commerciaf 38% 38% cial use only andf significagnific
nce for thece for th
t is statistis statis
ted if the if th
zed usinged usin
ts with mts with m
s. . d
forf
SC group C grou
nsure a rasure a
cal responrespocia
nn-e applicable Terms of Usee from from 
eroids at roids a
Week 52Week [ADDRESS_89553] of the study  that will be made to 
study  sites (and, if applicable, invest igators and/or other study  staff) will be specified in the 
Clinical Study  Site Agreement(s). All invest igators and subinvest igators must declare potential
conflicts of interests to the s ponsor. The sponsor will provide a financial disclosure form that must  
be signed by  [CONTACT_82262]; in 
addition, any potenti al conflicts of interests that are not covered by  [CONTACT_82263] f orm 
shoul d be discl osed separately  to the sponsor prior to the start of the study  at thei r site.
All institutional affiliat ions of the invest igator and subinvest igator should be declared on thei r 
curriculum vitae, which must be provided to sponsor before the start of the study .
3.2 Principal Investigator/Coordinating Investigator 
[INVESTIGATOR_82241] a Signatory Coordinating Investigator [INVESTIGATOR_39736] m the invest igators who participate in 
the stu dy. Select ion criteria for thi s investi gator will include significant knowledge of the study  
protocol , the study  medicat ion, thei r experti se in the therapeutic area and the conduct of clinical 
research as well as study participat ion. The Signatory Coordinati ng Investigator will be required to 
review and sign the clinical study  report and by  [CONTACT_82264] i t accurately  describes the 
resul ts of the study .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89554] aspartate aminotransferase
CD Cro
hn’s disease
CDAI Crohn’s Disease Activity Index
Cmax maximum observed serum concentration
CNS central nervous system
CRP C-reactive proteinC
trough trough serum concentration levels 
DSMB Data Safety Monitoring Board
ECG electrocardiogram
ECL electrochemiluminescence
eCRF electronic case report formELISA enzyme-linked immunosorbent assay
EPX E-Pro eXchange
EQ-5D Euro Quality of Life-5D
ET Early Termination
FDA Food and Drug AdministrationFSH follicle-stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal(ly)
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCP healthcare provider
HCV hepatitis C virusHIV human immunodeficiency virus
HRQOL health-related quality of life 
IAC Independent Adjudication Committee
IB Investigator’s Brochure
IBD inflammatory bowel diseaseIBDQ inflammatory bowel disease questionnaire
ICH International Conference on Harmonisation
ID identification
IEC independent ethics committee
IM intramuscular(ly)
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Usebent assaynt ass
-5DD
onn
ug Adming Adm
timulatingmulati
Clinical Clinica
astrointesroint
hepatitihepa
hephe
L
CC
IBB
IBDIBD
IBCCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89555]
ITT intent-to-treat
IV intravenous(ly)
IWRS interactive web response systemJCV John Cunningham virus
LFT liver function test
mAb monoclonal antibody
MAdCAM-[ADDRESS_89556] complaint
PK pharmacokinetic(s)
PML progressive multifocal leukoencephalopathy
PP per protocol
PRO patient-reported outcome
PTE pretreatment event
PVC polyvinyl chloride
Q2W once every [ADDRESS_89557] upper limit of normal
VAS visual analog scale
VCAM-1 vascular cell adhesion molecule-1
WBC white blood cell
Property of [COMPANY_005]: on-commercial use only and subject to the applicable Terms of Uselopathypathy
eeksks
[ADDRESS_89558] 2017
3.4 Corporate Identification
TPC [COMPANY_005] Pharmaceutical Company Limited
TDC Asia [COMPANY_005] Development Center Asia, Pte Ltd
TDC Europe [COMPANY_005] Development Centre Europe Ltd.
TDC Americas [COMPANY_005] Development Center Americas, Inc.
TDC TPC, TDC Asia, TDC Europe and/or TDC Americas, as applicable[COMPANY_005] TPC, TDC Asia, TDC Europe and/or TDC Americas, as applicable
3.5 Study Definitions
Term DefinitionClinical remission by A Crohn’s Disease Activity Index (CDAI) score ≤150.
Corticosteroid-free 
remissionSubjects using oral corticosteroids at Baseline (Week 0) who have discontinued oral 
corticosteroids and are in clinical remission at Week 52.
Disease worsening A ≥100 point increase in CDAI score from the Week 6 value on 2 consecutive visits and a
minimum CDAI score of 220 points.
Durable clinical 
remissionClinical remission at Week 6 and Week 52.
Enhanced clinical 
responseA ≥100 point decrease in CDAI score from Baseline (Week 0).
Treatment failure Defined as disease worsening, need 
for rescue medications (as defined in Section 7.3.1) , or 
need for surgical intervention for treatment of Crohn’s Disease.
Property of [COMPANY_005]: For non-commercial use onsteroids aroids 
n clinicalclinica
se in CDAin CD
core ore of f2
sion at Won at W
[ADDRESS_89559] 2017
4.0 INTRODUCTION
4.1 Background
4.1.1 Diseases and Current Treatments 
Inflammatory bowel disease (IBD) is a chronic, relapsing, inflammatory disorder of the 
gastrointestinal (GI) tract that includes 2 entities, namely ulcerative colitis (UC) and Crohn’s 
disease (CD). 
CD is a relapsing, remitting inflammatory disease th at may involve any portion of the length of the 
GI tract from mouth to anus in a transmural fashion from mucosa to serosa. The prevalence of CD 
is approximately 150/100,000 of the US population and approximately 125/100,000 of population 
in Western Europe [1-3] and 21.2/100,000 of the population in Japan [4]. The characteristic 
pathology involves a chronic inflammatory infiltrate consisting of neutrophils and macrophages. 
Hallmarks of CD include granulomatous inflammation and aphthous ulceration.
Clinical manifestations of CD include diarrhea, as well as abdominal pain, fecal urgency, and 
incontinence. Systemic features such as fever, weight loss, malaise, and fatigue are indicators of 
more extensive disease. Extra-intestinal manif estations such as uveitis, arthritis, ankylosis 
spondylitis, or primary sclerosing cholangitis may also be seen in conjunction with IBD. The 
diagnosis of CD is usually made by [CONTACT_82265].
Because in CD, clinical manifestations are not n ecessarily correlated with endoscopic and 
radiographic findings of disease activity [5], and as further evidence has emerged on the predictive 
potential of endoscopic improvement on long term clinical outcomes [6-8] endoscopic 
assessments have been incorporated in clinical studies for therapeutic outcomes evaluation. 
Currently, limited endoscop ic data in CD patients exists and are inconsistent due to lack of a 
validated definition of endoscopic mucosal healing, guidelines for scoring mucosal lesions and for 
the appropriate timing of assessment, as well as of cutoff values for disease severity and response 
to therapy [9,10] .  
 
 
 
Current treatments have been effective for many patients with CD but have numerous limitations 
for patients with moderately to severely activ e disease. The National Cooperative Crohn’s Disease 
Study demonstrated a role for sulfasalazine (a 5-aminosalicylate [5-ASA]) in moderately to 
severely active CD [11]. However, the efficacy of 5-ASAs in CD has been called into question by 
a recent meta-analysis [12].
Corticosteroids are often required for the patien ts who fail to respond to 5-ASAs. While highly 
effective for induction of remission, corticos teroids are not recommended for the maintenance of Property of TCurrenCurre
fofor par 
StuSon-commercial use only and subject to the applicable Terms of Usee 
d Crohn’Crohn
on of then of th
a. The prThe pr
125/[ZIP_CODE]/10
n n [[4]4]. ThT
f neutroneutr
hthous uhthous
abdoabdo mimi
oss, malss, ma
ns such ns suc
y also bey also b
ologic exogic ex
are not nare no
itiy y [[5][ADDRESS_89560] ive CD. Their relatively slow onset of 
action precludes their use during flares of disease, and the use o f these agents has been reported to 
potenti ally increase the ri sk of lymphoma in patients with IBD [13].
Methotrexate has a role in the management of refractory  CD; however, it also demonstrates a 
number of dose -limiting toxicit ies. Ant ibiotics have marginal efficacy in maintenance of remissio n 
in CD.
Biologic agents, incl uding m onoclonal antibodies (mAbs) against tumor necrosis factor -alpha
(TNF -α), such as infliximab (Remicade), adalimumab (Humira) and certolizumab pegol (Cimzia), 
have proven useful for both induction and maintenance of clinical response and clinical remissio n 
in CD [14-16] . However, efficacy data for both infliximab and adalimumab in CD indicate only a 
minori ty of patients having a durable response at 1 year [
17,18] . Certolizumab pegol as 
maintenance therapy was studied only up to [ADDRESS_89561] ive CD populat ion with more substant ia
l outcomes in the 
subgroup of patients with baseline C -reactive protein (CRP) ≥10 mg/L [19,20] . In addit ion to i ts 
modest efficacy , treatm ent wi th TNF -α antagonists has been associated with serious adverse 
events (SAEs) invo lving hypersensit ivity and infecti on. Reactivations of latent tuberculosis (TB) 
[
21]and disseminated histoplasmo sis have been reported and, in so me cases, have been fatal [22]. 
A new class of therapy , the integrin inhibitors, has shown promising results to date. In tegrin 
antagonists target and disrupt the leukocy te adhesion and trafficking systems, thereby  [CONTACT_82266]. Natalizumab (Tysabri ), a pan -
α4(α4β7and α 4β1) integrin antagonist was approved 
by [CONTACT_2165] (FDA) in [ADDRESS_89562] therapy  [23]. However, due to the antagonizi ng effect of natalizumab on α 4β1, whi ch 
mediates T -cell migration into the central nervous system (CNS), bone marrow, and skin via 
adhesio n to its ligand, vascular cell adhesio n mo lecul e
-1 (VCAM1), natalizumab therapy has bee n 
associ ated wi th increased ris k of John Cunningham virus (JCV) react ivation and subsequent 
development of progressive mult ifocal leukoencephalopathy (PML). As a result, natalizumab is 
cauti ously prescribed for the treatment of CD . 
Surgical remo val o f highly diseased, strictured, or st enotic segments of bowel in CD is not 
curative. Relapse occurs in a majorit y of patients wit h CD who undergo segmental resect ions, and 
the need for additional surgery is the rule rather than the except ion [24]. The limitat ions of current 
therapi [INVESTIGATOR_82242] a significant need for safer and more effect ive therapi[INVESTIGATOR_014].
4.1.2 Vedolizumab
Vedolizumab (also known as MLN0002) is a novel reco mbinant humanized mAb co mposed of 
2light chains o f the subclass and 2 immunoglobulin G1 heavy chains. Vedolizumab binds 
specifically to the human lymphocy te integrin 47. The α 4β7integrin mediates lymphocy te 
trafficking to GI mucosa and gut
-associated lymphoid tissue through adhesive interaction with 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89563] 2017
mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is expressed on the 
endothelium of mesenteric lymph nodes and GI mucosa [25-28] . As a result, vedolizumab impairs 
the migration of gut-homing leukocytes into GI mucosa [29] and acts as a gut-selective 
immunomodulator.
Vedolizumab IV (also known as ENTYVIO; KYNTELES; Vedolizumab for Injection, for 
Intravenous Use; Vedolizumab Powder for Concentrate for Solution for Infusion; or MLN0002 
IV) has been granted marketing approval in several regions, including the [LOCATION_002] and 
European Union. Vedolizumab IV is approved for the treatment of adult patients with moderately 
to severely active UC and CD, who have failed conventional treatment, such as 
immunomodulators, corticosteroids, or TNF- α antagonists. The approved dosing and 
administration regimen is 300 mg vedolizumab IV infused intravenously at Weeks 0 and 2, then 
once every 8 weeks (Q8W) thereafter, beginning at Week 6.
Vedolizumab subcutaneous (SC) (also known as Vedolizumab Injecti on, for Subcutaneous Use; 
Vedolizumab Solution for Injection in Pre-filled Syringe; or MLN0002 SC) is a new liquid 
presentation that has been developed for SC administration.  
 
 
 
 
Therefore, the nonclinical and clinical information from studies 
with vedolizumab IV are considered relevant.
As of 19 May 2015 (data lock point), more than [ADDRESS_89564] 1 dose of 
vedolizumab across all studies in the clinical development program. Phase 3 placebo-controlled 
studies enrolled 2427 subjects w ith UC or CD, of whom 1434 subjects were administered 300 mg 
of vedolizumab IV for induction followed by [CONTACT_39773] 4 weeks (Q4W) or Q8W for up to a total 
of 52 weeks and 488 subjects were administer ed 300 mg vedolizumab for induction only [30-32] . 
As of 19 May 2015, vedolizumab exposure has extended for ≥12 months in 1667 subjects, 
≥24 months in 1306 subjects, ≥36 months in 935 subjects, ≥48 months in 676 subjects, 
≥60 months in 267 subjects, and ≥[ADDRESS_89565] recent drug 
shipment data (19 November 2015), the cumulative patient exposure to vedolizumab since its 
marketing approval in May [ADDRESS_89566] characterized the efficacy, safety, tolerability, 
pharmacokinetic (PK), pharmacodynamic, and immunogenicity of vedolizumab in healthy 
subjects and subjects with UC or CD. Please refer to the current edition of the Investigator’s 
Brochure (IB) for the most recent data for vedolizumab.
[IP_ADDRESS] Nonclinical
Nonclinical in vitro and in vivo studies have been conducted with vedolizumab and its murine 
homologue, Act-1. Act-1 has demonstrated clinical and histomorphologic evidence of efficacy in 
an animal model of IBD (cotton-top tamarins). Extensive nonclinical evaluations of the Property of [COMPANY_005]: For non-commercial use  subject to the applicable Terms of Useor 
MLN000MLN0
States anates a
s with mwith 
as s 
dosing aosing a
ly at Wey at W
njeectiction
MLN000MLN00
n. 
the non
vantnt..
mmore thore t
the clinice clin
with UC ith U
tioon n fofoll
ects wercts we
dolizumlizum
subjectubje
67 subjec7 subj
(19 Nov([ADDRESS_89567] 2017
cardi ovascular, acute, loc al, subchroni c, chroni c, immunol ogic, and reproductive toxicit y of 
vedo lizumab in pharmaco logically responsive species (New Zealand white rabbit s and 
cyno molgus monkeys) have been conducted and support its clinical development. Nonclinical 
studi es also sho w that vedolizumab does not antagonize 41integrin [29].
A single -dose l ocal tolerance study  was conducted to determine the local irritancy potential of 
vedo lizumab SC when administered by  [CONTACT_82267]. Macroscopic and histological 
examinat ions of the injection sites indicated no findings o f concern with the vehicle or formulated 
vedo lizumab SC . 
[IP_ADDRESS] Clinical Experience With Vedolizumab IV
Single-and mult iple-dose PK of vedo lizumab have been studied in healt hy subjects and in subjects 
with moderately  to severely active UC or CD and similar PK was observed. Vedolizumab exhibit s 
target -mediated drug disposit ion; hence, its elimination is characterized by [CONTACT_82268]. Following IV infusio n, vedo lizumab serum concentrations generally fell in a 
biexponent ial fashion until approximately 1 to 10 µg/mL, with a linear total body  clearance of 
approximately  0.157 L/day  and a serum  half-life of around [ADDRESS_89568] ive CD (Study  C13007), including subjects who had 
failed treatment with 1or more therapi[INVESTIGATOR_39737] -α antagonists, vedo lizumab IV 300 mg at 
Weeks 0 and 2 (induct ion) fo llowed by 300 m g either once every  4 weeks (Q4W) or Q8W from 
Week 6 through Week 52 (m aintenance) demo nstrated statistically significant differences in 
efficacy  com pared to pl acebo for both the induct ion phase and m aintenance phase . The study  met 
its primary  endpoint for the induct ion phase , clinical  remissi on at Week 6, but did not meet the 
second primary  endpoint of enhanced clinical response (CDAI -100) at Week 6 in the overall 
popul ation although the treatment difference favored vedo lizumab (Table 4.a). The study did meet  
its primary endpo int fo
r the maintenance phase , clinical remissio n at Week 52, as well as impo rtant 
secondary  endpoints, including enhanced clinical response at Week 52 and corticosteroid- free 
clinical remissio n at Week 52 (Table 4.b) [31] . 
Table 4.a Efficacy of Vedolizumab IV in Subjects W ith C DDuring the Induction Phase 
(Week 6, C13007)
EndpointPBO
N=148VDZ
N=220 Difference p-value
Primary endpoint
Clinical remission (%) 6.8 14.5 7.8 0.0206
Enhanced clinical respons e 25.7 31.4 5.7 0.2322
Source: C13007 Clinical Study Report .
PBO=placebo, VDZ=vedolizumab.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89569] 2017
Table 4.b Efficacy of V edolizumab IV in Subjects With C D During the Maintenance 
Phase (Week 52, C13007)
EndpointPBO
N=153VDZ
Q8W
N=154VDZ
Q4W
N=154Difference
Q8W vs PBO
Q4W vs PBO p-value
Primary endpoint
Clinical remission (%) 21.56 39.0 36.4 17.4
14.70.0007
0.0042
Secondary endpoint
Enhanced clinical 
response at Week 52 
(%)(a)30.1 43.5 45.5 13.4
15.30.0132
0.0053
Corticosteroid -free 
clinical remission at 
Week 52(%) (b)15.9 31.7 28.8 15.9
12.90.0154
0.0450
Source: C13007 Clinical Study Report .
PBO=placebo, VDZ=vedolizumab.
(a) Enhanced clinical response is defined as a ≥100 -point reduction in CDAI score from Baseline.
(b) Corticosteroid-free clinical remission is defined as subjects using oral corticosteroids at Baseline who had 
discontinued corticosteroids and were in clinical remission at Week 52.
In Study  C13011, vedolizumab IV (300 mg at Weeks 0, 2, and 6) was administered to subjects 
with moderately or severely act ive CD who had failed convent ional therapi[INVESTIGATOR_014], including TNF- α 
antagonists. The primary endpo int of clinical remission at Week [ADDRESS_89570] failure 
intent-to-treat (ITT) populat ion was not met; however, a treatment difference was observed at 
Week [ADDRESS_89571] naïve [32].
Vedolizumab has shown an acceptable safet y profile based on an analysis o f safet y data from both 
completed and ongoing studies (see current version of IB). In phase 1 and 2 clinical trials 
(7completed phase 1 studies in healthy subjects and 8 completed phase 1b/[ADDRESS_89572] s), there was no consistent evidence of any dose -toxicity relationships, and vedo lizumab 
was well -tolerated. The m ajority of the safet y data is fro m 3 well -controlled, phase 3 clinical 
studi es that eval uated the safet y of vedolizumab IV for up to 12 months in subjects with UC 
(Study C13006 [52 weeks]) or CD (Studies C13007 [52 weeks] and C13011 [10 weeks]). In 
addition, an interim safet y assessment i s available for an ongoing lo ng-term open -label extensi on 
(OLE) study  (C13008), in which subjects are administered vedolizumab IV Q4W.
In the pi[INVESTIGATOR_30338] 3 studies (C13006 and C13007), the most commo n (≥5% and at a higher
incidence than placebo) adverse reactions in subjects administered vedo lizumab IV were nausea, 
nasopharyngit is, upper respi[INVESTIGATOR_39738], arthralgia, py
rexia, fat igue, headache, and 
cough. Most serious adverse events (SAEs) have been related to e xacerbat ions or complicat ions of 
the underlying UC or CD. For those infect ions that were reported more frequent ly in 
vedo lizumab -treated subjects, the sites of these infections correlated with the known t issue 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89573] ions (bronchit is, 
pneumo nia, urinary  tract infect ion, sepsis) occurred at low frequency (<1%). A total of 4% of 
vedo lizumab -treated s ubjects and 3% of placebo -treated subjects experienced an infusio n-related 
reacti on. In Studi es C13006 and C13007, 10% of subjects were posit ive for antivedo lizumab 
antibodies [ADDRESS_89574] an increased risk for malignancy  with vedo lizumab treatment. Overall, the 
safet y profile fo llowing l ong-term treatm ent wi th vedolizumab IV in Study  C13008 is consistent 
with safet y in the completed studies. 
Concomitant use of cor ticosteroi ds and/or convent ional immuno modulators di d not appear to be 
associ ated wi th any increased rate of infect ions based on the comparative rates of infections in the 
phase [ADDRESS_89575] dose of vedo lizumab was administered. The causes of death varied and detailed information 
can be found in the current edition of the IB. 
Overall, vedo lizumab was well tolerated in clinical studies .
[IP_ADDRESS] C
linical Experience With Vedolizumab SC
The feasibilit y of administering the vedo lizumab IV formulat ion by [CONTACT_82269] (IM) injection was explored in an open -label, single dose, parallel -group 
bioavailabilit y study  (C13010) in healt hy male subjects. In this study , 42 subjects were enrolled 
and 14 subjects each received a single dose of 180 mg vedolizumab IV as IV infusio n (over 
30minutes), SC inject ions (2 × 1.5 mL × 60 mg/mL), or IM injections (2 × 1.5 mL × 60 mg/mL). 
Following SC administrati on, absorpti on of  vedo lizumab was gradual, achieving maximum 
concentration at [ADDRESS_89576] ion (time to reach maximum serum concentration). The 
maximum observed serum concentration (C max) following SC inject ion was approximately 1 /3 of 
the C maxfollowing 30 minute IV infusio n. There was no difference in the terminal eliminat ion 
profile of the SC cohort compared to the IV cohort, indicating that the eliminat ion of vedo lizumab 
is not absorption rate -limited. The abso lute bioavailabil ity of vedo lizumab was approximately 
75% for SC administration. Vedo lizumab was well tolerated when administered at a dose of 
180mg by [CONTACT_57982]. Five of the 14 subjects (36%) in the IV infusio n cohort and 3 of the 
14 subjects (21%) in the SC cohort ex perienced a drug -related AE (assessed by [CONTACT_3170]). 
Most AEs were mild or moderate in severit y. Three of the 14 subjects (21%) in the IV infusio n 
cohort and 2 of the 14 subjects (14%) in the SC cohort in this study were ant i-vedo lizumab 
antibody  (AVA) posi tive using the originally developed AVA assay that was used in the phase 3 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89577] 2017
studies with vedolizumab IV. While all 3 AVA positive subjects in the IV infusion cohort had 
neutralizing AVA, no neutralizing AVA was observed in the SC cohort.
The bioavailability and PK of vedolizumab following a single SC injection of vedolizumab SC at 
3 dose levels (54, 108, and 160 mg) relative to a single IV infusion of vedolizumab IV 300 mg was 
examined in a phase 1, open-label study (MLN0002SC-101). Forty-eight (24 Japanese and 
24 non-Japanese) healthy, adult male and female subjects were randomized. A total of 12 subjects 
received a single dose of vedolizumab IV 300 mg and 36 subjects received a single dose of 
vedolizumab SC at 54, 108, or 160 mg (12 subjects per dose group).
The bioavailability following a single SC injection of vedolizumab SC was 75.1%, independent of 
the vedolizumab SC dose evaluated (54, 108, or 160 mg). Vedolizumab reached maximum serum 
concentrations around 1 week after a single SC injection. Vedolizumab was eliminated by [CONTACT_82270], with more rapid elimination with 
decreasing dose/concentration. Compared with non-Japanese subjects, Japanese subjects generally 
showed similar or slightly higher exposure; howev er, ethnicity did not have an impact on clearance 
or central volume of distribution based on the populat ion PK analysis, likely due to the fact that 
weight was included as a covariate for various population PK parameters. Simulations further 
confirmed that vedolizumab SC at 108 mg every 2 weeks (Q2W) is expected to provide lower 
trough concentrations at steady state than vedolizumab IV 300 mg Q4W and similar steady-state 
exposures (average serum concentration at stead y state) as the approved vedolizumab IV 300 mg 
Q8W maintenance regimen.
An electrochemiluminescence (ECL) assay has been developed to determine serum titers of AVA. 
This assay has improved drug tolerance as comp ared with the prior enzyme-linked immunosorbent 
assay (ELISA) method used in the vedolizumab clinical development program and, as a result, is 
more sensitive. Both assays were used in Study MLN0002SC-101; the ECL assay data were used 
in the analysis of PK and safety.
Overall, 75.0% (36/48) of subjects had treatment-emergent adverse events (TEAEs), and the 
percentage of subjects with a TEAE was ident ical in sub jects who received vedolizumab SC 
compared with subjects who received vedolizumab IV. All TEAEs were considered by [CONTACT_82271]; no TEAEs of severe intensity were reported. The 
percentage of subjects with mild or moderate TEAEs was similar between subjects who received 
vedolizumab SC and vedolizumab IV; the percentages were also similar across the dose groups. 
No subjects had clinical laboratory test results, vital signs, or electrocardiogram (ECG) results that Property of TOveOveralra
perceper
comercial use only and subject to the applicable Terms of UseC at at 
mg was mg was 
nd 
1212subjsu
e dose ofdose o
75.1%, in.1%, i
reached mached
b was elwas 
apid elimid el
bjects, Jacts,
y dy did not id no
PK analyK analy
on PK pan PK
weeks (Qeeks (Q
umab IVmab IV
adyystatestatyy
say has bay has
ce as coe as 
vedoedolizl
re used ie use
y.y.
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89578] 2017
were reported as AEs. Two subjects had elevated bilirubin levels that met the predefined markedly 
abnormal value criteria; howev er, no subject had abnormal liver function test (LFT) results 
involving aspartate aminotransferase (AST) or alanine aminotransferase (ALT).
Two AEs of special interest were reported: [ADDRESS_89579] in the vedolizumab SC 
160 mg group experienced an injection site reaction. Both events occurred on Day 1 and were 
observed at the 30 minute postdose observation time point (a protocol -defined time point). In each 
case, the event resolved at the 1.5 hour postdose observation time point and was considered by [CONTACT_82272]. Both subjects recovered without any 
sequelae.
 
 
No SAEs, severe AEs, or deaths were reported in Study MLN0002SC-101. The observed AEs are 
consistent with the overall safety profile of vedolizumab.
4.2 Rationale for the Proposed Study
As IV infusion may not be convenient as long-ter m therapy for some patients, vedolizumab SC has 
been developed to enable injection by [CONTACT_82273]. 
This phase 3 study is designed to evaluate  the efficacy, safety, PK, and immunogenicity of 
multiple injections of the new presen tation, ve dolizumab SC, as maintenance therapy in subjects 
with CD. 
 
Therefore, all nonclinical and 
clinical information from studies with vedo lizumab IV is cons idered relevant. 
The vedolizumab exposure-efficacy r elations hip has been demonstrated in UC subjects in the 
phase 3 vedolizumab IV study (C13006), where higher serum vedolizumab concentrations were 
associated with higher eff icacy (Source: Population PK Efficacy Report 2013). Although the 
exposure-efficacy relationship demonstrated in UC subjects was not as clear in CD subjects 
participating in the vedolizumab IV phase 3 studies, the vedolizumab SC dosing regimen selection 
is applicable to CD subjects based on the following important considerations:
!Vedolizumab targets the same mechanism of action in both the UC and CD indications. 
!Vedolizumab IV was effective in inducing and maintaining remission in subjects with 
moderately to se verely active UC or CD who had failed conventional and/or TNF- α antagonist 
therapy. Property of [COMPANY_005]: Fmatmat
lizumablizuma
3 vedovedo lil
ciiated wated 
exposureexposu
partiparci
is aimercial use only and subje he applicable Terms of Usemab SC ab SC
nd werend we
poipointnt))I
consideronsid
coveredovere
yMLN0MLN
umab.mab.
ongng--termte
patpatieientntso
valuate taluate
ressentatienta
CCICCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89580] 2017
!No differences in PK, safety, or immunogenicity between the UC or CD subjects were 
observed in the vedolizumab IV phase 3 studies.
The proposed vedolizumab SC maintenance dosing regimen (108 mg Q2W) was selected to 
provide lower steady- state trough concentrations than the vedolizumab IV Q4W dosing regimen 
and similar C avgsteady-state exposures to that from th e approved vedolizumab IV Q8W dosing 
regimen, and the safety and efficacy of the vedolizumab SC presen tation are expected to be similar 
to those of vedolizumab IV, outside of expected local administration site events, such as 
injection-site r eactions.
4.3 Benefit:Risk Assessment
The proposed study (MLN0002SC-3031) is designed to evaluate the efficacy and safety of 
vedolizumab SC as maintenance therapy in subjects with moderately to severely active CD who 
achieved clinical response following open-label vedo lizumab IV therapy. Because IV infusion 
may not be convenient as long-term therapy, vedolizumab SC has been developed to ultimately 
enable injection by [CONTACT_82273].  
 
. Therefore, the 
nonclinical and clinical information from studies with vedolizumab IV are considered relevant.
The study population in Study MLN0002SC-3031 is consistent with the approved vedolizumab IV 
label. The proposed vedolizumab SC maintenance dosing regimen (108 mg Q2W) was selected to 
provide similar steady- state exposure to that from the approved vedolizumab IV dosing regimen 
(300 mg Q8W). It is expected that similar steady-state exposure to vedolizumab will result in 
similar maintenance efficacy, independent of the dosing route or presentation. In addition, safety 
of the vedolizumab SC presentation is expected to be similar to that of vedolizumab IV due to 
similar exposure, outside of expected local administration site events, such as injection-site 
reactions.  
The observed AEs with 
vedolizumab SC are consistent with the vedolizumab IV safety profile. 
Overall, vedolizumab has been well tolerated in clinical studies, including a phase 1 study of 
vedolizumab SC, and has a positive benefit-risk profile in the treatment of CD.
Property of [COMPANY_005]: For mmercial use only bject to the applicable Terms of Useimen imen 
dosing osing 
to be simo be s
uch as ch as 
fficacyficacy ay
ly to sevy to s
therapyherap
hahas bees be
with vedt
[ADDRESS_89581] 2017
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objective(s)
!To assess the effect of vedolizumab SC maintenance treatment on clinical remission at 
Week 52 in subjects with moderately to severely active CD who achieved clinical response at 
Week 6 following administration of vedolizumab IV at Weeks 0 and 2.
5.1.2 Secondary Objectives
!To determine the effect of vedolizumab SC maintenance treatment on enhanced clinical 
response at Week 52 in subjects who achieved clinical response at Week 6 following 
administration of vedolizumab IV at Weeks 0 and 2.
!To determine the effect of vedolizumab SC maintenance treatment on corticosteroid-free 
remission at Week 52 in subjects who achieved clinical response at Week 6 following 
administration of vedolizumab IV at Weeks 0 and 2.
!To assess the effect of vedolizumab SC maintenance treatment on clinical remission at 
Week [ADDRESS_89582] 2017
5.2 Endpoints
5.2.1 Primary Endpoints
!Proportion of subjects with clinical remission, defined as CDAI score ≤150, at Week 52.
5.2.2 Secondary Endpoints
!Proportion of subjects with enhanced clinical response, defined as a ≥100 point decrease in 
CDAI score from Baseline (Week 0), at Week 52.
!Proportion of subjects with corticosteroid-fr ee remission, defined as subjects using oral 
corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52.
!Proportion of TNF- α antagonist naïve subjects who achieved clinical remission, defined as 
CDAI score ≤150, at Week 52.
5.2.3 PRO Endpoints
!Changes in inflammatory bowel disease questionnaire (IBDQ) total score and subscores, from 
Baseline (Week 0) to Week 52 and from Week 6 to Week 52.
!Changes in Euro Quality of Life-5D (EQ-5D) ut ility scores and EQ-5D visual analog s cale 
(VAS) score from Baseline (Week 0) to Week 52 and from Week 6 to Week 52.
!
 
Property of [COMPANY_005]: For non-commercial use only and subject tned as Cd as C
ical respal resp
at Week Week
steroiteroidd
ek 0) whk 0) w
2.
tagonist agonis
Week 52Week 
ointsnts
inflammnflamm
(Week 0Week
nges in ges in E
ASS))scoscf UseCCI
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89583] ive CD is defined as described in Inclusio n Cri teria (Secti on7.1).
Subjects who are either TNF -α antagoni st naïve or with TNF -α antagonist failure will be inc luded 
ensuring approximately 50% of subjects with TNF -α antagonist failure are enrolled . Subjects with 
previous use of TNF -α antagoni st but not failed will be included ensuring that no more than 10% 
of such subjects are enrolled.
The study  includes a 4-week(28-day) Screening Period, a [ADDRESS_89584] ion Phase , and a 46 -week rando mized, double
-blind, placebo -controlled Maintenance Phase 
with vedolizumab SC wi th final visit at Week 52. 
Eligible subjects will be enro lled into the Indu ction Phase at Week 0, will receive open -label 
infusio ns of vedo lizumab IV 300 mg at Weeks 0 and 2, and will be assessed for clinical response 
by [CONTACT_82274] (defined as a ≥70 point decrease in CDAI score from Baseline [Week 0]) at Week 6 , as 
follows:
Subjects who achieve a clinical response at Week 6 will be rando mized into the Maintenance 
Phase. Upon complet ion of the Week 52 assessment or upon early discont inuat ion due t o 
treatm ent failure (i e, disease worsening after Week 6 or need for rescue medicat ionsafter 
Week 14 ) these subjects will be eligible to enter the OLE study (Table 7.a).
Subjects who do not achieve a clinical respo nse at Week [ADDRESS_89585] infusio n of vedo lizumab IV 300 mg at 
Week 6. Subjects who achieve a clinical response at Week 14 (by  [CONTACT_82274]) will be eligible to 
enroll in the OLE study . Subje cts who respond but choose not to enroll in the OLE study  and 
subjects who do not achieve clinical response at Week 14 will be discont inued. 
Subjects who achieve a clinical response at Week 6 will be rando mized at a 2:1 ratio to receive 
blinded injections of vedolizumab SC 108 mg or placebo SC Q2W, beginning at Week 6 through 
Week 50. 
Randomization will be stratified by:
Concomitant use of oral corticosteroids.
Clinical remissio n status at Week 6.
Previous TNF -
α antagonist failure /exposed or concomitant immuno modulator (azathi oprine, 
6-mercaptopurine, or methotrexate) use.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89586] 2017
At Week 6, subjects receiving oral corticosteroids who achieved a clinical response and are 
randomized into the Maintenance Phase will begin a corticosteroid tapering regimen.
After receiving training from the health care provi der (HCP; investigator or designee) on the 
proper SC injection technique and how to manage hype rsensitivity reactions potentially associated 
with the injection, subjects or their caregivers will inject vedolizumab SC or placebo SC under the 
supervision of the HCP during at least the Week [ADDRESS_89587] 
observation of any potential hypersensitivity or injection site reactions associated with SC 
injection and timely intervention by [CONTACT_82275]. Subjects and caregivers may attend the clinic at 
Weeks 10 and 12 if further training is required. Sub jects or their caregivers will also administer SC 
injections during the scheduled clinic visits at Weeks 14, 22, 30, 38, 46, and 50 under the 
supervision of the HCP to allow continued observation of injection technique and AEs; all other 
scheduled SC injections should occur outside of  the clinic. HCPs will have appropriate monitoring 
and treatment for hypersensitivity reactions av ailable for use following administration of study 
drug. Subjects who experience a severe hypersens itivity reaction associated with study drug 
administration will be discontinued from the study (see Section  7.4). 
Subjects and their caregivers will be instructed to inject SC doses into the thigh, abdomen, or upper 
arm, and to rotate the injection sites. Subjects and their caregivers will be instructed that the upper 
arm is to be used only when the caregiver administers the SC injection. Details on the training 
protocol and injection technique will be included in  the appropriate Study Manual. For all dosing 
occurring outside of the clinic, subjects will receive a phone call from study staff within [ADDRESS_89588] and 
enquire about general health status and experience with prior injection. In accordance with the 
Risk Assessment and Management Plan for PML (RAMP), any positive PML subjective finding 
must be evaluated via the physician administered PML objective checklist prior to the subject 
receiving the respective dose (refer to RAMP Site Staff Brochure). Subjects will also receive a 
phone call from their HCP within [ADDRESS_89589] udy or are discontinued from the study be fore Week
6, will enter the Follow-Up Period and complete a final on-study safety assessment at 18 weeks (ie, 
5 vedolizumab half-lives) after the last study drug dose. 
Additionally, subjects who do not participate in  the OLE study or a discontinued before Week 6
will be required to par ticipate in a long-term follow-up (LTFU) safety survey by [CONTACT_756], [ADDRESS_89590] dose of study drug.
 
 
 Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Useociated ociated 
under thnder t
injectinject io
w for direor di
d wiwiththiiiiSh
ttend theend th
will alsowill als
, and 50and [ADDRESS_89591] SC dot SC d
their careir ca
inististers ters
uded in uded in
will receill rec
duled dosuled do
and expend ex
ent Plan nt Plan
sician adician 
se (refere (ref
CP withiP with
nd experiexpe
bject wilect w
do not pdo not
thhe Fole F
zumab humab
itioionallynal
ill ill be rebe r
momonth
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89592] 2017
A schematic of the study design is included as  Figure 6.a.  A schedule of assessments is listed in 
Appendix A.
Property of [COMPANY_005]: For non-commercial use onFigurFigu UseCCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89593] 2017
Figure 6.a Schematic of Study Design
WEEK 6 RESPONDERS
Screening
PeriodInduction 
PhaseMaintenance 
PhaseFollow -up 
PeriodAdditional
Follow -up
LTFU Safety 
Survey by 
[CONTACT_10880] (b)
(6months 
after the last dose 
of study drug)Final Safety 
Visit (b) 
(18weeks after 
the last dose of 
study  drug) OL 
Vedolizumab IV 
300mgResponder:
Vedolizumab SC 
108mg Q2W
or
Placebo SC Q2WEnd-of-Study  
(a)/
ETproceduresR
OLE Study  
MLN0002SC -
3030 (c)
Days Wk Wk Wk Wk Wk Wk
-28to -1 0 6 7 51 52 68
Visit: 1 2 5 6 14 15 16
WEEK 6 NONRESPONDERS
Follow -up 
PeriodAdditional
Follow -up
Responder at 
Wk14OLE Enroller
(d)OLE Study  
MLN0002SC -
3030 (c)
Nonresponder at Wk 6:
Vedolizumab IV 
300mgOLE 
nonenroller (d)
Nonresponder at 
Wk 14:
OLE Nonenroller 
(d)Discontinued
Final Safety Visit 
(b) 
(18weeks after the 
last dose of study 
drug)LTFU Safety 
Survey by 
[CONTACT_10880] (b)
(6months 
after the last dos e 
of study drug)
Days Wk Wk Wk
-28 to -1 0 6 14
Visit :1 2 5
Figure 6.a footnotes on next page.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89594] 2017
OL=open -label, R=randomization.
(a) Maintenance P eriod: Subjects who ET(Table 7.a) may consent to participate in the OLE study 
(MLN0002 SC-3030) and may enter the OLE study and begin OLE study dosing after End-of-Study Visit procedures 
have been completed.
(b) For subjects who do not enroll into the OLE study (MLN0002SC-3030) (including early  terminators before 
Week 6in the Maintenance Phase) 
(c)First visit of OLE Study MLN0002SC -[ADDRESS_89595] dose of study drug for Week 52 
completers/ET or 1 week of Week 14 for Week 14 responders .
(d) Week 14 responders and nonresponders (OLE enroller/nonenroller) will complete the procedures as per the 
Schedule of Assessments ( Appendix A).
6.[ADDRESS_89596] ions of the new presentation, vedo lizumab SC, as maintenance therapy in subjects 
with CD. The proposed vedolizumab SC mainte nance dosing regimen (108 mg Q2W) was 
selected to provide similar exposure to that from the approved IV vedo lizumab dosing regimen 
(300 m g Q8W). Therefore, the safety  and efficacy  of the vedo lizumab SC presentation are 
expected to be similar to those of ve dolizumab IV, outsi de of expected l ocal administrati on si te 
events, such as inject ion-site reacti ons. 
The study  design allows for independent assessments of vedo lizumab SC efficacy as maintenance 
therapy  in subjects who responded to vedolizumab IV by  [CONTACT_82276] . It also permits double -blind, pl acebo -controlled 
comparisons of safet y param eters duri ng the Maint enance Phase . Addi tional measures will be 
taken to collect safet y parameters bey ond the 52 -week duration of the trial, where a Final Safety
Follow
-up V isit will be conducted 18 weeks (>5 half -lives) after the subject’s final dose of study  
drug if they do not enroll in the OLE, and addit ional safet y information will be co llected by 
[CONTACT_5791] a LTFU survey at [ADDRESS_89597] study  drug dose (for both SC and IV 
dosing) . 
The entry  criteria ensure that subjects who are appropriate for treatment with bio logic agents, as 
assessed by  [CONTACT_82277] 1or more st andard therapi[INVESTIGATOR_014] (ie, corticosteroids, 
immuno modulators, or TNF -α antagonists), will be enro lled into the study. Entry criteria will also  
exclude subjects who might not benefit fro m drug or who might be at risk for treatment toxicit ies. 
Addit ional measures to ensure the safet y of enrolled subject s include protocol mandated criteria 
for withdrawal  from the study  of subjects who experi ence worsening of disease or require rescue 
medicat ion (ie, any  new medicat ion or any  increase in dose of a baseline medication required to 
treat new or unresolved CD symptoms, other than ant idiarrheals for con trol of chroni c diarrhea). 
Thus, subjects who may be treated with placebo (inactive treatment) between Weeks 6 and 52 will 
be wit hdrawn fro m the study  if they experience treatment failure (ie, disease worsening after 
Week 6, need for rescue medicat ionsafter Week 14 ), but m ay be eligible to enroll in the OLE 
study .
At Week 6, subjects receiving oral corticosteroids who achieve clinical response must begin a 
corticosteroi d tapering regimen as described in Section
 [IP_ADDRESS] . Subjects are allowed to continue 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89598] 2017
background therapy such as 5-ASAs or immunomodulators, as indicated in the Permitted 
Medications and Treatments in Section 7.3.1.
The primary efficacy endpoint of this study is  clinical remission, defined as a CDAI score 
≤[ADDRESS_89599] assessment tool to measure CD disease activity in clinical trials 
[36], . CDAI includes 3 subjective items 
(number of liquid stools, abdominal pain and general wellbeing), and 5 objective items (number of 
extraintestinal complications, use of antidiarrheal drugs, presence of abdominal mass, hematocrit, 
and ideal/observed body weight ratio).  
 
Exposure-efficacy analyses were conducted using either observed or population model predicted 
vedolizumab concentrations from the phase 3 vedolizumab IV studies. In both the quartile analysis 
using the C trough and the logistic regression analysis us ing the population PK model predicted C av
(Cav=AUC τ/τ), there was an apparent exposure-efficacy relationshi p in subjects with UC for both
the Induction and Maintenance Phases, where higher vedolizumab concentrations were associated 
with higher efficacy. Although the exposure-efficacy  relationship demonstrated in UC subjects 
was not as clear in CD subjects participating in the vedolizumab IV phase 3 studies, the 
vedolizumab SC dosing regimen selection is applicable to CD subjects based on the following 
important considerations:
!Vedolizumab targets the same mechanism of action in both the UC and CD indications. 
!Vedolizumab IV was effective in inducing and maintaining remission in subjects with 
moderately to se verely active UC or CD who had failed conventional and/or TNF- α antagonist 
therapy. 
!No differences in PK, safety or immunogenicity between the UC or CD subjects were observed in the vedolizumab IV phase 3 studies. 
Based on the exposure-efficacy relations hip for vedolizumab IV, the vedolizumab SC dosing 
regimen was selected to provide lower trough concentrations than the vedolizumab IV Q4W 
regimen and similar exposure to that from the approved vedolizumab IV Q8W regimen (300 mg 
vedolizumab IV at Weeks 0 and 2, followed by 300 mg Q8W starting from Week 6) during the 
Maintenance Phase. It is expected that similar exposure to vedolizumab will result in similar 
efficacy and safety during maintenance, independent of the dosing route or formulation.
In addition to efficacy and safety evaluat ions, the multiple dose PK and immunogenicity of 
vedolizumab SC in subjects during the Maintenance Phase will be evaluated in this study. Given 
the long half-life of vedolizumab (approximately 25 days), blood samples will be collected up to 
18 weeks (>5 half-lives) after the last dose to assess the PK of vedolizumab IV followed by 
[CONTACT_82278]. Property of [COMPANY_005]: For non-commercial use only and subjec he applicable Terms of Usemab mab 
the studythe stud
ity y in clin 
subjectbject iviv
bjectctive iive
bdominami
erved orrved o
b IV studIV stu
ing the png the 
cacycyrelareyy
gher vedher ve
efficacyficacy y
ng in thein th
on is appis ap
e mechamech
cttive ive ini
y actactive Uive
in PK, san PK, 
izumab Iumab
e exposuexpos
was selewas se
en and sn and 
olizumalizum
MaintenMainte
efficaeffi
InCCI
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89600] 2017
During the Maintenance Phase of this study, vedolizumab SC or placebo SC injections will be 
administered by [CONTACT_82279] (Weeks 6, 8, 14, 22, 30, 38, 46,
and 50 under HCP supervision) and outside of the clinic. HCPs will train the subjects (and their 
caregivers) on the adequate technique to prepa re and inject study drug during at least at the Week [ADDRESS_89601] udy.
!New information or other evaluation regarding the safety or efficacy of the study medication 
that indicates a change in the known risk/benefit profile for the product, such that the 
risk/benefit is no longer acceptable for subjects participating in the study.
!The Data Monitoring Co mmittee recommends the study s hould be su spended or terminated. 
!Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary study objectives or compromises subject safety.
6.3.2 Criteria for Premature T ermination or Suspension of Investigational Sites
A study site may be terminated prematurely or suspende d if the site (including the investigator) is 
found in significant violation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study, or as otherw ise permitted by [CONTACT_82280].
6.3.3 Procedures for Pre mature Termination or Suspension of the Study or the 
Participation of Investigational Site(s)
In the event that the sponsor, an IRB/independent  ethics committee (IEC) or regulatory authority 
elects to terminate or suspend the study or the participation of an investigational site, a Property of [COMPANY_005]: For non-commercial use onlyn of Stu of St
ation or ion o
ed unlessd unle
arlylytermtermyy
valuataluat io
n the knthe kn
ger acceper acc
ring Coing Co
iolatatioion
ryry studystudyy
Criteria riteri
udydysisiyyte tiiii
und in sund in
adequaadequ
6cable Terms of Useeek [ADDRESS_89602] 2017
study -specific procedure for early  terminat ion or suspensio n will be provided by  [CONTACT_456]; the 
procedure will be fo llowed by [CONTACT_82281].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89603] 2017
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including test results, need to be confirmed prior to first dose. 
7.[ADDRESS_89604] eligibilit y is determined according to the following criteria prior to entry  into the study : 
1.In the opi[INVESTIGATOR_1649] o f the invest igator, the subject is capable of understanding and complying wit h 
protocol  requi rements.
2.The subject or, when appli cable, the subject’s legally acceptable representative signs and dates 
a wri tten, informed consent form and any  required privacy  authori zation prior to the init iation 
of any study  procedures.
3.The subject has a diagnosis of CD established at least [ADDRESS_89605] who is nonsterilized* and sexually active wit h a female partner of childbearing 
potenti al* agrees to use adequate contraception* from signing of informed consent throughout 
the duration of the study  and for [ADDRESS_89606] of childbearing potential* who i s sexually act ive with a nonsterilized* male 
partner agrees to use routinely adequate contraceptio n* fro m signing of informed consent 
throughout the duration of the study  and for [ADDRESS_89607] dose. 
*Definit ions and acceptable methods of contr aceptio n are defined in Sect ion9.1.[ADDRESS_89608] dose of study  drug and 1 of the fo llowing:
CRP l evel >2.87 m g/L during the Screening Period OR
Ileocol onoscopy  with photographi c docum entation of  a minimum  of 3 nonanastom otic 
ulcerat ions (each >0.5 cm in diameter) or 10 aphthous ulcerations (involving a minimum o f 
10 contiguous cm o f intestine) consistent with CD, within 4 months prior to Screening OR
Fecal calprotectin >250 mcg/g stool during the screening period in conjunction wit h
computed tomography  enterography , magnetic resonance enterography , contrast -enhanced 
small bowel radiography, or wireless capsule endoscopy  revealing CD ulcerations 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89609] 2017
(aphthae not sufficient), within 4 months p rior to screening. (Subjects with evidence of 
fixed stenosis or small bowel stenosis with prestenotic dilatation should not be included). 
8.The subject has CD invo lvement of the ileum and/or colon, at a minimum.
9.Subjects with extensive co litis or pancolit isof >8 years duration or left -sided co litis >[ADDRESS_89610] docum ented evidence that a surveillance co lonoscopy  was perform ed 
within 12 m onths of the init ial Screening Visit (if not performed in previous [ADDRESS_89611] 
be perform ed during Scr eening).
10.Subjects with a family history  of colorectal  cancer, personal history  of increased col orectal  
cancer risk, age >[ADDRESS_89612] be up -to-date on colorectal cancer 
surveillance (may be perform ed during Screening) .
11.The sub ject has demo nstrated an inadequate response to, loss of response to, or intolerance of 
at least 1 of the following agents as defined below:
Immunomodulators:
i. The subject has signs and symptoms of persistent ly active disease despi[INVESTIGATOR_040] a history of at 
least o ne 12-week regime n of oral  azathi oprine ( ≥1.5 mg/kg) or 6 -mercaptopurine 
(≥0.75 mg/kg), or, at least one 8 -week regimen of oral azathioprine ( ≥50mg) or 
6-mercaptopurine ( ≥30 m g) (Japan only) OR
ii. The subject has signs and symptoms of persistent ly active disease despi[INVESTIGATOR_040] a hi story  of at 
least one 16 -week regimen of methotrexate of 25 mg/week OR
iii. The subject has a history  of intolerance of at least 1immuno modulator (including, but 
not limited to nausea/vo miting, abdominal pain, pancreat itis,LFT abnormalit ies, 
lymphopenia, thiopurine S -methyltransferase geneti c mutation, infect ion).
Corti costeroi ds
i. The subject has signs and symptoms of persistent ly active disease despi[INVESTIGATOR_040] a history of a 
least one [ADDRESS_89613] ion regimen that included at dose equivalent to predniso ne 
≥30mg daily orally for [ADDRESS_89614] has a history of into lerance of corticosteroids (including, but not limited to, 
Cushing’s syndrome, osteopenia/osteoporosis, hyperglycemia, ins omnia, and 
infect ion).
iv. The subject had a relapse wit hin 3 months of stoppi[INVESTIGATOR_82243].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89615] 2017
TNF -α antagoni sts:
i. The subject has signs and symptoms of persistent ly active disease despi[INVESTIGATOR_040] a history of at 
least 1induction wit h:
Infliximab: At least 4 -week regimen o f 5 mg/kg, 2 doses at 2 weeks apart, OR
Adalimumab: At least 80 mg on Day  1 and 40 m g on D ay 15, OR
Certolizumab pego l: At least [ADDRESS_89616] (including, but 
not limited to infusio n-related reacti on, demyelinatio n, congestive heart failure, 
infect ion).
7.2 Exclusion Criteria
The exclusio n criteria are divided into 3 categories: gastrointest inal, infect ious disease, and 
general. Any subject who meet s any o f the following criteria will not qualify  for entry  into the 
study : 
7.2.[ADDRESS_89617] has a history  of >[ADDRESS_89618] igational or appro ved non -biologic therapi [INVESTIGATOR_014] 
(eg,cyclo sporine, tacrolimus, thalido mide, methotrexate, or tof acitinib except for those 
specifically listed in the protocol Sect ion 7.3.1 Permitted Medicat ions for the Treatm ent of 
CD) for the treatment of underlying disease within 30 days or 5 half -lives of screening 
(whichever is longer).
7.The subject has received any invest igational or approved bio logic or bi osimilar agent within 
60days or 5 half-lives of screening (whichever i s longer). 
8.The subject has used topi[INVESTIGATOR_2855] (rectal) treatment with 5 -ASA or corticosteroid 
enem as/supposi tories wi thin [ADDRESS_89619] currently requires or is ant icipated to require surgical intervent ion for CD duri ng 
the study .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89620] has chronic hepat itis B virus (HBV) infect ion* or chronic hepat itis C virus (HCV) 
infect ion.
* HBV immune subjects (ie, being hepat itis B surface antigen [HBsAg] negat ive and hepat itis 
B surface antibody [HBsAb] positive) m ay, however, be included.
16.The subject has act ive or latent TB as evidenced by [CONTACT_3162]:
i. A posi tive di agnosti c TB test within 30 days prior to screening or during the screening 
period, defined as:
1.A posi tive QuantiFER ON test or 2 successive indeterminate QuantiFERON tests, 
(or,A posit ive T -SPOT TB test [Japan only ]), 
OR,
2.A tuberculin skin t est reaction ≥5 mm.
Note: if subjects have received BCG vaccin e then a QuantiFERON TB Gold tes t 
shoul d be perform ed instead of the tuberculin skin text
OR
ii. Chest X -ray within 3 m onths pri or to Week 0 which is suspi[INVESTIGATOR_82244], 
and a posi tive or 2 successive indeterminate QuantiFERON tests (or, A posit ive 
T-SPOT TB test [Japan only]) within 30 days prior to Screening or during the 
Screening Period.
Note: subjects with documented previously treated TB with a negat ive Quant iFERON 
test can be included in the study.
17.The subject has any ident ified congenital or acquired immunodeficiency (eg, commo n var iable 
immunodeficiency , human immunodeficiency virus [HIV] infection, organ transplantation).
18.The subject has received any live vaccinat ions wit hin [ADDRESS_89621] ion (eg, pneumo nia, pyelo nephrit is) within [ADDRESS_89622] ion.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89623] igational anti-integrin antibodies
(eg, natalizumab, efalizumab, etrolizumab, AMG 181) ,anti-MAdCAM -[ADDRESS_89624] has any  unstable or uncontrolled cardiovascular, pulmo nary, hepatic, renal, GI, 
genitourinary , hematol ogical, coagul ation, immunological, endocrine/metabo lic, or other 
medical disorder that, in the opi[INVESTIGATOR_3078] n of the invest igator, woul d confound the study  resul ts or 
compromise subject safet y.
24.The subject has had any surgical procedure requiring general anesthesia within [ADDRESS_89625] has any  history  of malignancy , except for the following: (a) adequately -treated 
nonmetastati c basal cell skin cancer; (b) squamous cell skin cancer that has been adequately 
treated and that has not recurred for at least 1 year prior to screening ; and (c) history of cervic al 
carcino ma in situ that has been adequately treated and that has not recurred for at least 3 years 
prior to screening . Subjects with remote history of malignancy (eg, >10 years since complet ion 
of curative therapy  without recurrence) will be considered b ased on the nature of the 
malignancy and the therapy received and must be discussed with the sponsor on a case -by-case 
basis prior to screening .
26.The subject has a history  of any major neurol ogical disorders, including stroke, mult iple 
sclerosi s, brain tum or, or neurodegenerative disease.
27.The subject has a posit ive PML subject ive symptom checklist at Screening (or prior to the 
administration of the first dose of study  drug at Week 0 ).
28.The subject has any  of the f ollowing laboratory  abnorm alities during the S creening Period:
i. Hem oglobin level  <8 g/dL.
ii. White blood cell (WBC) count <3 × 109/L.
iii. Lymphocy te count <0.5 × 109/L.
iv. Platelet coun t <100 × 109/L or >1200 × 109/L.
v. ALT or AST >3 × the upper limit of normal (ULN).
vi. Alkaline phosphatase >3 × ULN.
vii. Serum  creatinin e >2 × ULN.
29.Removed inAmendment [ADDRESS_89626] has a history  of drug abuse (defined as any  illici t drug use) or a hi story  of alcohol  
abuse within 1 y ear pri or to screening . 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89627] has an active psychiatric problem that, in the investigator’s opi[INVESTIGATOR_21677], may interfere 
with com pliance wi th study  procedures.
32.The subject or caregiver is unable to attend all the study visits or comply with study 
procedures.
33.The subject is required to take excluded medications listed in Section 7.3.
34.The subject is unwilling or unable to self-inject , or does not have a caregiver (defined as a lega l 
adult) to inject the study  medicat ion.
35.Female subjects who are lactating or have a posit ive serum pregnancy test during the 
Screening P eriod or a posi tive urine pregnancy test at Week 0, prior to study  drug 
administration.
36.If female, the subject is intending to beco me pregnant before, during, or within 18 weeks after 
participat ing in this study ; or intending to donate ova during such t imeperiod. 
37.If male, the subject intends to donate sperm during the course of this study  or for [ADDRESS_89628] of this study  (eg, spouse, 
parent, child, sibling) or may consent under duress. 
7.3 Excluded Medications and Treatments
The fo llowing m edicat ions are excluded fro m use during the study (from informed consent to 
Week 68) : 
Any treatment for CD othe r than those listed in Section 7.3.1 (either approved or 
investigat ional).
All live vaccines fro m [ADDRESS_89629] dose of study 
drug.
Either approved or invest igational biological agents for the treatment of non -IBD condi tions, 
other than localized inject ions (eg, intra -ocular injecti ons for wet m acular degenerat ion).
Chronic nonsteroidal ant i-inflammatory  drug (NSAID) use. (Note: occasional use of NSAIDs 
and acetami nophen for headache, arthrit is, myalgias, menstrual cramps, etc. and daily use o f 
baby [INVESTIGATOR_1660] l ow-dose [81- 162.5 mg] aspi[INVESTIGATOR_82245].)
Leukocy tapheresis (white blood apheresis) or granulocy tapheresis (Japan only).
Enteral n utrients (>900 kcal /day) (Japan only).
Subjects m ust be instructed not to take any  medicati ons, including over- the-counter products, 
without fi rst consul ting wi th the investi gator.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89630] 2017
7.3.1 Permitted Medications and Treatments 
The subject may be receiving a therap eutic dose of the fo llowing drugs: 
–Oral 5-ASA co mpounds provided that the dose has been stable for the [ADDRESS_89631] dose of study drug . The doseof these medications shoul d rem ain 
stable throughout the study .
–Oral corticosteroid ther apy (prednisone at a stable dose ≤30 mg/day, budesonide at a stable 
dose ≤9 mg/day, or equivalent steroid) provided that the dose has been stable for the [ADDRESS_89632] meets the 
criteria for init iating a corticosteroid tapering regimen (see Sect ion [IP_ADDRESS] ).
–Probi otics (eg, Culturelle, Saccharomyces boulardii ) provided that the dose has been stable 
for the [ADDRESS_89633] dose of study  drug . The dose for these 
medicat ions should remain stable throughou t the study .
–Antidiarrheals (eg, loperamide, diphenoxylate with atropi[INVESTIGATOR_050]) for control of chronic 
diarrhea . Stable doses are encouraged.
–Azathioprine , 6-mercaptopurine , or methotrexate provided that the dose has been stable for 
the [ADDRESS_89634] dose of study  drug . Dose(s) should remain stable 
unless the medication is discontinued due to a toxicity related to the medication. Even if the 
toxicity resolved, azathi oprine, 6 -mercaptopurine, or methotrexate will not be restart ed.
–Antibiotics used for the treatment of CD (eg, ciprofl oxacin, metronidazo le) provided that 
the dose has been stable for the [ADDRESS_89635] dose of study drug. The
doseof these medicat ions should remain stable throughout the study.
For immunosuppr essives, oral [ADDRESS_89636] ions. For oral corticosteroid, 
as per the tapering schedule (see Sect ion
 [IP_ADDRESS] ).
Enteral nutrients ( ≤900 kcal /day), stabl e for at l east 3 weeks pri or to enrollment. The dosage 
may be modified after Week 6;however it should preferably remain the stable dose and not 
exceed the init ial dosage (Japan only).
Need for rescue m edication : In thi s study , any new medicat ion or any  increase in dose of a 
baseline medication required to treat new or unresolved CD symptoms (other than 
antidiarrheals for control of chronic diarrhea) is considered a rescue medicat ion. An increase in 
corticosteroi d dose back to baseline for subject s undergoing corticosteroid tapering within the 
guidelines presented in Sect ion [IP_ADDRESS] is not considered rescue medicat ion. Administration o f 
rescue m edicati ons, appr oved or invest igational, constitutes treatment failure. Rescue 
medicat ions should not be withheld if, in the opi[INVESTIGATOR_35272], failure to prescribe 
them woul d com promise subject safet y.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89637] 2017
[IP_ADDRESS] Oral Corticosteroid Dosing and Tapering 
At Week 6, subject s receiving oral corticosteroids who achieved clinical response will begin a 
corticosteroi d tapering regimen. The tapering schedule is as fo llows: 
For predni sone at doses >10 mg/day  (or equivalent), the dose should be reduced at a rate of 
5mg/week unt il a 10 m g/day  dose is reached. 
For prednisone at doses ≤10 mg/day (or equivalent) or once a 10 mg/day dose (or equivalent) is 
achieved by [CONTACT_39782], the dose should be reduced at a rate of 2.5 mg/week unt il 
discontinuat ion.
For budesonide, the dose should be tapered at a rate of [ADDRESS_89638] ion therapy  (shoul d 
not exceed baseline dose). In such cases, the tapering regimen above must be reinit iated within 
2weeks. Subjects who require consistent higher doses should be withdrawn fro m the study  
according to Section 7.4.
Current ly, there is no evidence to support the routine prophylactic administration of premedicat ion 
(eg, antihistamines, corticosteroids) to subjects receiving vedo lizumab; hence, such premedicat ion 
is unlikely  to be necessary  or beneficial. At the discretion of the inves tigator, however, subjects 
may be administered premedicat ion prior to any  study  drug administration. Corticosteroids, if 
given as a premedication, should be limited to the day  of administrati on. 
7.[ADDRESS_89639] from  the study  or study 
medicat ion shoul d be recorded in the electronic case report form (eCRF) using the fo llowing 
categori es. For screen failure subjects, refer to Sectio n 9.1.2 2.
1.Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires early 
termination because cont inued participat ion imposes an unacceptable risk to the subject’s 
healt h or the subject is unwilling to c ontinue because of the PTE or AE.
LFT Abnorm alities.
Study  medicati on shoul d be discont inued immediately with appropriate clinical fo llow
-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status, Se ction 9.1.9 ), if the fo llowing ci rcumstances occur at any  time 
during study  medicat ion treatment:
–ALT or AST >8 × ULN, or
–ALT or AST >5 × ULN and persists for more than 2 weeks, or
–ALT or AST >3 × ULN in conjunc tion wi th elevated total  bilirubin >2 × ULN or 
internat ional norm alized rati o (INR) >1.5, or
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89640] 2017
–ALT or AST >3 × ULN with appearance of fat igue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).
2.Significant proto col deviat ion. The discovery  after the first dose of study  medicat ion that the 
subject failed to meet protocol entry  criteria or di d not adhere to protocol requirements, and 
continued participation poses an unacceptable risk to the subject’s health.
3.Lost t o follow -up. The subject did not return to the clinic and attempts to contact [CONTACT_39783]. Three attempts to con tact the subject must be documented (ie, 2 attempts 
by [CONTACT_17084] 1 attempt by  [CONTACT_50202] l etter).
4.Voluntary  withdrawal. The su bject (or subject’s legally acceptable representative) wishes to 
withdraw from  the study . The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an 
AE or l ack of  efficacy shoul d not be recorded in the “vo luntary withdrawal” category ).
5.Study  terminat ion. The sponsor, IRB, IEC, or regulatory  agency  terminates the s tudy.
6. Pregnancy. The subject is found to be pregnant. 
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion 9.1.[ADDRESS_89641] shoul d be discont inued fro m the study  if the fo llowing cri teria 
apply:
Treatment failure during the Maintenance Phase , defined as disease worsening (as defined 
in Section 3.5), need for rescue medicat ions (as defined in Sect ion 7.3.1 ), or need for 
surgi cal interventi on for treatm ent of  CD.
8.Leukopenia or Lymphopenia: WBC and lymphocyte counts will be monitored for all subjects. 
Azathioprine, 6- mercaptopurine, o r methotrexate, if applicable, should be discontinued and the 
dose of study drug held for an abso lute lymphocy te count <0.5 × 109/L at any po int in the study. 
The abso lute lymphocy te count m ust be repeated at appropriate intervals as determined by  [CONTACT_1275]. The next dose of study  drug can be administered only if the absolute lymphocy te 
count is ≥0.5 × 109/L. If the abso lute lymphocyte count remains <0.5 × 109/L, study drug should 
be discont inued and the subject withdrawn from the study.
9.Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
Subjects who discont inue due to lack of efficacy are permitted to enroll in the OLE study 
(MLN0002SC -3030) according to the criteria in
 Table 7.a.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89642] 2017
Table 7.a Eligibility for Study MLN0002SC -3030 Based on Reason for Withdrawal 
Reason for WithdrawalTime Point
Prior to Week 6 Weeks 6 -14 Beyond Week 14
Disease worsening (a) Not applicable Eligible Eligible
Requires rescue medication, but does not meet 
criteria for disease worsening Not applicable Not e ligible Eligible
AE related to study drug leading to discontinuation 
of study drug Not eligible Not eligible Not eligible
Requires surgical intervention for CD Not eligible Not eligible Not eligible
(a) See Section 3.5for study  definitions .
7.[ADDRESS_89643]’s stud y participat ion at any t ime during the study when 
the subject meets the study termination criteria described in Section 7.4. In addition, a subject may 
discontinue his or her participat ion without giving a reaso n at any time during the study. Should a
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
[CONTACT_3170]. In addit ion, efforts should be made to perform all procedures scheduled for the ET 
Visit(if appli cable), Final Safet y Visit,and LT FU. Discontinued or withdrawn subjects will not be 
replaced.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89644] ion contains informat ion regarding all medicat ion and m aterials provi ded di rectly by [CONTACT_103], and/or sourced by  [CONTACT_11174], that are requi red by [CONTACT_23643] , including 
important sections describing the management of clinical trial material.
8.1 Study Medication and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
In thi s protocol , the term  study  medication refers to all or any  of the drugs defined below: 
[IP_ADDRESS] Vedolizumab for Injection, for Intravenous Use (Vedolizumab IV)
The study  sites will be supplied by [CONTACT_82282] -label 
manner: vedo lizumab IV 300 mg/vial, for single use, in [ADDRESS_89645] a single -panel or mult ilingual booklet label that will contain, but will not be 
limited to the following: sponsor’s name [CONTACT_3816], protocol number, packaging job/lot number, 
name [CONTACT_82321], medicat ion identificat ion number , subject informat ion, caution 
statement, di rections f or use, and storage condit ions.
There i s no pl acebo IV for this study .
Addit ional reference informat ion and administration instructions can be found in the Pharmacy 
Manual. 
[IP_ADDRESS] Vedolizumab Injection, for Subcutaneous Use (Vedolizumab SC)
The study  sites will be supplied with the following medicat ion in a blinded manner: vedo lizumab 
SC 108 m g/0.[ADDRESS_89646] a single -panel or mult ilingual booklet label that will contain, but will not be 
limited to the following: sponsor’s name [CONTACT_3816], protocol number, packaging job/lot n umber, 
name [CONTACT_82321], medicat ion identificat ion number, subject informat ion, caution 
statement, di rections f or use, and storage condit ions.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89647] 2017
[IP_ADDRESS] Sponsor -Supplied Drug
Sponsor -supplied drugs referenced in other sections of the protocol include the following:
Vedolizumab for Injection, for Intravenous Use (vedolizumab IV).
Vedolizumab Inject ion, for Subcutaneous Use (vedolizumab SC)/vedo lizumab SC placebo.
[IP_ADDRESS] Other Protocol -Specified Materials
The fo llowing supplies will also be required for study drug administration and are to be provided 
by [CONTACT_82283]:
Bottl ed sterile water for inject ion (for study  drug reconst itution).
250 mL 0.9% sodium chloride for inject ion in po lyvinyl chloride (PVC) IV bag(s) or 250 mL 
0.9% sodium chloride in alternative IV bags or bottles listed in the Pharmacy Manual. (100 mL 
in Japan).
PVC infusio n line or alternative infusio n line listed in the Pharmacy Manual.
Alcoho l swabs.
Needle sharps container (provided by  [CONTACT_3211]).
8.1.[ADDRESS_89648] be stored at 2ºC to 8ºC (36ºF to 46ºF). A daily 
temperature l og of  the drug storage area must be maintained every working day.
8.1.3 Dose and Regimen
The dose and dosing regimen for all s ubjects i s provided in Table 8.a.
Table 8.a Dose and Regimen 
Treatment Group Dose Treatment Description
All Subjects Vedolizumab IV 300 mg Open -label Weeks 0 a nd 2
A (Week 6 
Nonresponders)Vedolizumab IV 300 mg Open -label Week 6
B Vedolizumab SC 108 mg Blinded Weeks 6 -50 (Q2W)
C Vedolizumab SC Placebo Blinded Weeks 6 -50 (Q2W)
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89649] according 
to the study  protocol .
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eC RF, in order to capture this important safety  information consistent ly in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs associated 
with an overdose will be documented on AE CRF(s) according to Section 10.0, Pretreatment 
Events ,Adverse Events (AEs), and Product Complain ts (PC) .
SAEs associated with overdose should be reported according to the procedure outlined in 
Secti on10.2.[ADDRESS_89650] igator’s designee will access the interactive web response system 
(IWRS) at screening to register a subject and obtain a subject ident ification number to ident ify the 
subject throughout the study . The invest igator or the invest igator’s designee will use the IWRS to 
enroll the subject into the study. The medication ident ificat ion (ID) number of the invest igational 
drug to be dispensed will then be provided by  [CONTACT_82284]. If
sponsor -supplied drug is lost or damaged, the site can request a replacement from IWRS. Refer to 
the appropriate study  manual  provided separately for addit ional informat ion. 
For IV infusio n, subjects will receive a [ADDRESS_89651] ion, the recommended sites are the abdomen (except for the 2 -inch area around the 
navel), the outer area of the upper arms, or the front of the thighs. The arm inject ion site should be 
used only by  [CONTACT_82285]. The inject ion site should be changed for 
consecut ive inject ions. Each new injection should be given at least [ADDRESS_89652] (or caregiver) under the 
supervisio n of a HCP prepared to manage hypersensit ivity react ions including anaphylaxis, if the y 
occur. Appropriate monitoring and medica l support measures should be available for immediate 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89653].
For further dispensing informat ion, please refer to the pharmacy and/or appropriate study  manual.
8.3 Randomization Code Creation and Storage
After receiving open -label infusio ns of vedo lizumab IV 300 mg at Weeks 0 and 2, subjects will be 
assessed for clinical res ponse (defined as a ≥70 point decrease in CDAI score from Baseline 
[Week 0]) at Week 6). Subjects with clinical response at Week 6 will be rando mized at a 2:[ADDRESS_89654] ions of vedo lizumab SC 108 mg or placebo SC Q2W, beginning at Week 6 
through Week 50.
Randomization will be stratified by:
Concomitant use of oral corticosteroids.
Clinical remissio n status at Week 6.
Previous TNF -α antagonist failure /exposed or concomitant immuno modulator (azathi oprine, 
6-mercaptopurine, or methotrexate ) use.
Randomization personnel of the sponsor or designee will generate the randomizat ion schedule 
prior to the start of the study . An IWRS system  will be used for subject randomizat ion. All 
rando mizat ion informat ion will  be stored in a secured area, acces sible only  by [CONTACT_39792].
8.[ADDRESS_89655] be recorded in the source 
docum ents and eCRF as appropriate.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89656] ensure that the sponsor -supplied 
drug is used in accordance with the pr otocol  and is dispensed only to subjects enrolled in the study. 
To document appropriate use of sponsor- supplied drug, [vedolizumab IV vials and vedo lizumab 
SC/pl acebo SC pre -filled syringes], the appropriate person must maintain respect ive records of all 
sponsor -supplied drug delivery to the site, site inventory , dispensation, and use, by  [CONTACT_6992], 
and return to the sponsor or designee.
Records of the subject number, the date study  drug was di spensed, and the study  drug/cohort 
assignment will be mainta ined by  [CONTACT_32335].
Upon recei pt of sponsor -supplied drug, the appropriate pharmacist must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantit y is correct, and the 
medicat ion is in good condit ion. If quant ity and condit ions are acceptable, they  shoul d 
acknowledge the receipt of the shipment (by [CONTACT_82286] o f the packing list and faxing 
per instructions provided on the form/ or by  [CONTACT_82287]). If there are any  discrepancies 
betwee n the packing list and the actual product received, [COMPANY_005] must be contact[CONTACT_82288]. The packing list should be filed in the invest igator’s essent ial document file (pharmacy file).
The pharmacist must maintain 100% accountabilit y for all spon sor-supplied drugs received and 
dispensed. Proper drug accountabilit y includes, but is not limited to:
Continuously mo nitoring expi[INVESTIGATOR_82246].
Frequent ly verifying that actual inventory  matches d ocum ented inventory .
Verifying that the log is completed for the (drug lot/medicat ion ID/job number) used to prepare 
each dose.
Verifying that all containers used/assigned are documented accurately on the log.
Verifying that required fields are co mpleted a ccurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The IWRS will include all required informat ion as a separate entry  for each subject to whom 
sponsor -supplied drug is dispensed.
The p harmacist m ust record the current inventory  of all sponsor -supplied drugs on a 
sponsor -approved drug accountabilit y log. The fo llowing informat ion will be recorded at a 
minimum: protocol number and tit le, name [CONTACT_4236], site ident ifier and number, descri ption 
of sponsor -supplied drugs, date and amount dispensed including init ials, date and amount returned 
to the site by  [CONTACT_423], and the init ials, seal, or signature [CONTACT_39844]. The 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89657] igator or desi gnee will 
retain a copy  of the docum entati on regarding sponsor -supplied drug accountabilit y, return, and/or 
destruction, and originals will be sent to the sponsor or designee.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89658] identification number (subject number) will be assigned by [CONTACT_82289]; this subject number will be used throughout the study.
9.1.2 Demographics, Medical History, and Medication History Procedure
Demographic information to be obtained will include age or date of birth (depending on local 
regulations), sex, Hispanic ethnicity (as applicable, [LOCATION_002] only), race as described by [CONTACT_82290]. 
Medical history to be obtained will include determining whether the subject has any significant 
conditions or diseases relevant to the dis ease under study that stopped at or prior to signing of 
informed consent. Ongoing conditions are considered concurrent medical conditions (see 
Section 9.1.8) .
Medication history information to be obtained includes any medication relevant to eligibility 
criteria stopped at or within 30 days prior to signing of informed consent.
Property of [COMPANY_005]: For non-cs, Mes, M
formatormat ioi
sex, Hispsex, Hi
d smokinmok
al historyhisto
dititiions oons
nformform ede
SectiSec o
Mect to the applicable Terms of Useedure, edure, 
The he
studystudy , an
ssigned bsigned
ghout thhout
CCI
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89659] 2017
9.1.3 Physical  Examination Procedure
A baseline physical examination (defined as the assessment prior to first dose of investigational 
drug) will consist of the following body systems: (1) eyes; (2) ears, nose, th roat; (3) cardiovascular 
system; (4) respi[INVESTIGATOR_2133]; (5) gastrointestinal system; (6) dermatologic system; 
(7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; (11) other. All 
subsequent physical examinations should assess clinically significant changes from the assessment 
prior to first dose examination.
9.1.[ADDRESS_89660] for collecting height is centimeters without decimal places and for 
weight it is kilograms (kg) with [ADDRESS_89661]. 
9.1.5 Vital Sign Procedure
Vital signs will include body temperature, re spi[INVESTIGATOR_697], blood pressure (sitting), and pulse 
(bpm). On dosing days, vital signs are taken predose. 
9.1.[ADDRESS_89662] be recorded throughout the study, including the Screening Period. A 
validated electronic system will be  used for co llection of the p atient diary.
On all dosing visits CDAI components are to be performed prior to dosing; the total CDAI score 
will be calculated once results are available for all components.
[IP_ADDRESS] Diary Completion and Review
Diary entries will be made daily by [CONTACT_82291], and will be used for 
CDAI calculation. At screening, subjects will be instructed on how to appropriately complete the 
daily diary. The symptoms of CD must be recorded throughout the study, including the Screening 
Period. Diary entries will be made daily by [CONTACT_36090] a validated electronic system. At 
each visit, including during screening, the CDAI sc ore must be calculated prior to dosing by [CONTACT_941] 
, accessed by [CONTACT_82292], 
laboratory assessments, and clinical examination and recorded in the subject’s source documents. 
The CDAI score evaluated during screening will be used to determine eligibility, using subject 
diary entries within [ADDRESS_89663] 14 days prior to Week 0.  
 Property of Ta : For non-commercial use only and subject to the applicable Terms of Useular ar 
other. Alher. A
e assessmasses
clothinglothin
decimal pcimal
, blblood pood p
ntenanceenance
ed on hoon h
ughout tghout 
sed for csed for 
onents arnents 
s are avaare av
on and Rn and
mmade dade
n. At screAt sc
e sympte symp
ryy entrieentriy
t, includ lu
oratoryorato ay
The CDThe C
didiara
[ADDRESS_89664] has achieved clinical 
response at Week 6 (a ≥70-point decrease in CDAI score fro m baseline [Week 0]), and will 
determine eligibilit y for randomizat ion in the Maintenance Phase .
Entri es shoul d be reviewed and mo nitored by  [CONTACT_941] s tudy staff (see the appropri ate Study  Manual). 
9.1.[ADDRESS_89665] taken any 
medicat ion other than the study  medicat ion (used from  signing of informed consent through the 
end of the study ), and all medicat ion includi ng vi tamin supplements, over -the-coun ter 
medicat ions, and oral herbal preparations, must be recorded in the eCRF. Medicat ions used 
specifically for premedicat ion purposes will be collected separately in the eCRF.
9.1.8 Documentation of Concurrent Medical Conditi ons
Concurrent medical condit ions are those significant ongoing condit ions or diseases that are present 
at signing of informed consent. This includes clinically significant laboratory , ECG, or phy sical 
examinat ion abnormalit ies noted at screening or baseline examinat ion. The condit ion (ie, 
diagnosis) should be described.
9.1.9 Procedures for Clinical Laboratory Samples
All samples will be co llected in accordance with acceptable laboratory  procedures at the time 
points specified in the schedule o f events. The maximum volume of blood at any  single visit i s 
approximately  24 m L, and the approximate total volume of blood for the study is 260 mL. Details 
of these procedures and required safet y monitoring will be given in the laboratory  manual.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89666] 2017
Clinical laboratory tests to be performed in this study are summarized in  Table 9.a.  Refer to the 
Schedule of Events in Appendix A for timing of all assessments. See Laboratory Manual for 
testing regimen.
Table 9.a Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis 
RBC
WBC w/ differential HemoglobinHematocritPlateletsPT/INRALT
AlbuminAlkaline phosphataseAmylaseLipaseAST Total and direct bilirubinTotal proteinCreatinineBlood urea nitrogen
Creatine kinase
GGTPotassiumSodiumCalciumChlorideBicarbonateMagnesiumPhosphorus Uric Acid Glucose Bilirubin
Blood GlucoseKetonesLeukocyte esteraseNitritepHProtein Specific Gravity 
Microscopic (to be 
obtained in the event of 
positive leukocyte esterase or blood, will include WBCs, RBCs, and cast[s])
Other:
HIVHepatitis panel, including HBsAg, HBsAb, and anti-HCV (a)CRPFecal Calprotectin
QuantiFERON for TB
PKBeta hCG and Urine Pregnancy hCG
(female subjects of childbearing potential)FSH (b)C. difficile
CRP= C-reactive Protein, FSH=follicle-stimulating hormone, GGT= γ-Glutamyl transferase, hCG=human chorionic 
gonadotropin, HBsAb=antibody to hepatitis B surface antigen, PT=prothrombin time, RBC=red blood cells.
(a) HBV immune subjects (ie, being HBsAg negative and HBsAb positive) may, however, be included.
(b) FSH level will be obtained for female subjects at Screening if they are postmenopausal by [CONTACT_969] (ie, last regular menstrual cycle >1 years) and not surgically sterile. The FSH result must be >40 IU/L for the subject to be permitted not to use adequate contraception.
Central laboratories will perform laboratory tests for hematology, serum chemistries, and 
urinalysis as well as specialty testing outlined above. The results of safety laboratory tests will be 
returned to the investigator, who is responsible for reviewing and filing these results. Refer to the 
schedule of events for timing of all assessments. Property of [COMPANY_005]: F on-commercial use only and subject to the applicable Terms of UseeT
cosese
Ketonestones
LeukocLeukoc
NitriNit
pHbl
rc
g, HBsAbHBsA
forfor TB Te
a: reactive Pactive
otropin, Hotropin, 
HBV immHBV im
b) FSH leb) FSH 
menstrumen
not tnotCCI
CCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89667] >3 ×ULN, follow -up laboratory tests should be performed 
within a maximum o f 7 day s and preferably within 48 -72 hours after the abnormalit y was noted.
(Please refer to Section 7.4for discont inuat ion criteria, and Sect ion 10.2.[ADDRESS_89668] >3 ×ULN in 
conjunction with total  bilirubi n >2 ×ULN.)
If the ALT or AST remains elevated >3 ×ULN on these [ADDRESS_89669] details and 
possible alternat ive et iologies. The abnormalit y shoul d be recorded as an AE (please refer to 
Secti on 10.2.3 Reporting of Abnormal Liver Functio n Tests for reporting requirements).
9.1.[ADDRESS_89670] 
dose of study  medicat ion, nonsterilized** male subjects who are sexually  active wi th a female 
partner of childbearing potential* must use barrier contraception (eg, condom with spermicidal 
cream  or jelly). In addi tion, they  must be advised not to donate sperm during this period.
From  signing of informed consent, throughout the duration of the study, and for 18weeks after last 
dose of study medicat ion, female subjects of childbearing potential* who are sexually act ive with a 
nonsterilized male partner** must use adequate contraception. In addit ion they  must be advised 
not to donate ova during this period.
*Females NOT of childbearing potential are defined as those who have been surgically sterilized 
(hysterectomy, bilateral oophorectomy or tubal ligation) or who are postmenopausal (eg, defined 
as at l east [ADDRESS_89671] regular menses wit h an FSH >40 IU/L o r at least [ADDRESS_89672] 
regul ar menses, confirmed before any  study  medicati on is implemented).
**Sterilized males should be at least [ADDRESS_89673] 
obtained documentation of the absence of sperm in the ejaculat e.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89674] 2017
An acceptable method of contraception is defined as one that has no higher than a 1% failure rate. 
In thi s study , where medicat ions and devices containing hormones are included, the only 
acceptable methods of contraception will be:
Barrier methods (eac h time the 
subject has intercourse):Intrauterine devices 
(IUDs):Hormonal contraceptives:
Male condom PLUS spermicide.
Cap (pl us spermicidal cream or 
jelly) PLUS male condom and 
spermicide.
Diaphragm  (plus spermicidal 
cream  or jelly) PLUS male 
condom  and spermicide.Copper T PLUS condom 
or spermicide.
Progesterone T PLUS 
condom  or spermicide.Implants.
Horm one shot/i njecti on.
Combined pi[INVESTIGATOR_4382].
Minipi[INVESTIGATOR_4382].
Patch.
Vaginal ring PLUS male 
condom  and spermicide.
Subjects will be provided with information on accept able methods of contraception as part of the 
subject informed consent process and will be asked to sign a consent form stating that they  
understand the requirements for avoidance of pregnancy, donation of ova, and sperm donation 
during the course of the st udy.
During the course of the study , subjects will receive continued guidance with respect to the 
avoidance of pregnancy as part of the study procedures ( Appendix A). 
All female subjects of child bearing potential will have a serum pregnancy test during screening 
and at Week 52 (or ET Visit) and Week 68 (or Final Safety Visit). A urine pregnancy  test will  be 
completed for all females of child bearing potential on a 4- weekly basis prior to administration of 
study  drug.
9.1.[ADDRESS_89675]’s partner.
If the pregnancy occurs during administration o f active study medicat ion or within [ADDRESS_89676] igator.
Subjects rando mized to placebo need not be fo llowed .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89677]/female part ner of the subject became 
pregnant and provide details of treatment the subject received.
All pregnancies in subjects on active study drug will be followed up to final outcome, using the 
pregnancy form. The outcome, including any premature termination, must be reported to the 
sponsor. An evaluation after the birth of the child will also be conducted.
9.1.[ADDRESS_89678] 12-lead ECG will be recorded. The investigator (or a qualified observer at the 
investigational site) will interpret the ECG us ing 1 of the following cate gories: with in normal 
limits, abnormal but not clinically significant, or abnormal and clinically significant. 
Any findings from ECGs collected after study drug administration at Week [ADDRESS_89679] to the applicable Terms of Useing the ng the
d to the d to the
d observobser
tegorigories:e
ically sigcally
ion at Won at W
inically snically
more minore m
nd the dthe
CCI
CCI
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89680] will be recorded as an AE in the eCRF. Additional 
information and tools for the RAMP can be found in the appropriate Study Manual. 
9.1.20 Patient Repo rted Outcomes Instruments 
Subjects will complete the IBDQ and EQ-5D health related quality-of-life (HRQOL) 
questionnaires at the time points specified in the schedule of events.  
.
[IP_ADDRESS] Inflammatory Bowel Disease Questionnaire
The IBDQ is a valid and reliable [ 37]instrument used to assess quality of life (QOL) in adult 
subjects with IBD. It includes 32 questions on 4 domains of HRQOL: Bowel Systems (10 items), 
Emotional Function (12 items), Social Functi on (5 items), and Systemic Function (5 items). 
Subjects are asked to recall symptoms and QOL from the last 2 weeks and rate each item on a 
7-point Likert scale (higher scores equate to higher QOL). A total IBDQ score is calculated by 
[CONTACT_82293]; the total IBDQ score ranges from 32 to 224.
[IP_ADDRESS] EQ-5D Questionnaire
The EQ-5D questionnaire, developed by [CONTACT_941] ‘EuroQol Research Foundation’ is a simple, valid, 
and reliable [38] instrument used to measure general h ealth-r elated QOL in  subjects and includes 5
domain items - mobility, s elf-care, usual activities, pain/discomfort, and anxiety/depression. 
Subjects choose the level of h ealth problems they currently have on each item as “None”, 
“Moderate”, or “Extreme” and are scored a 1, 2, or 3, respectively. A composite EQ-5D score can Property of [COMPANY_005]: For non-c entercial use only and subject to the applicable Terms of Usecile le assayassa
y when awhen 
o excludexclu
ive checve che
clinic. Tlinic.
when thwhen 
ll be toldbe t
testing ating 
orithm rrithm
l be recobe rec
e found found
 InstrumInstru
Q and EQand E
s specispe
y BowBowel ewww
lid and rd and
BD. It inBD. It 
unctnctiion
are askeare as
nt Likert Like
mming thmming 
[IP_ADDRESS]
ThCCI
CCI
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89681] been 
shown in many studies to be valid and reliable instruments for measuring HRQOL in patients with 
GI diseases.
[IP_ADDRESS]
 
 
 
 
 
 
 
 
 
9.1.[ADDRESS_89682] the IWRS 
as a notification of screen failure and complete the Screen Failure eCRF.
The primary reason for screen failure is recorded in the eCRF using the following categories:
!PTE/AE.
!Did not meet inclusion criteria or did meet exclusion criteria. Property of [COMPANY_005]:Documeocum
sttigatorigato
If tf the suhe s
as a nas a
Ty andcable Terms of Usewith with 
CCI
CCICCI
CCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89683] 2017
Significant protocol  deviat ion.
Lost to follow -up.
Voluntary  withdrawal <specify reason>.
Study  terminat ion.
Other <specify  reason>.
Subject numbers assigned to subjects who fail screening should not be reused. Re -screening of 
subjects will be assessed by [CONTACT_27216] a case by [CONTACT_413].
9.1.[ADDRESS_89684] source records.
9.3 Schedule of Observations and Procedures
The schedule for all study -related procedures for all evaluat ions is shown in Appendix A. 
Assessments should be co mpleted at the designated visit/time point(s).
9.3.[ADDRESS_89685] ion7.0. See 
Secti on9.1.22 for procedures for documenting screening failures.
Procedures to be completed at screening can be found in the schedule of events ( Appendix A). 
9.3.2 Enrollment/Rando mization 
Enrollment will take place at Week 0. If the subject has sat isfied all o f the inclusio n criteria and 
none of the exclusio n criteria, the subject should be enrolled using the IWRS. Subjects will be 
instructed on when the first dose of invest igational drug will be given as described in Sect ion6.1. 
The procedure for documenting screening failures is provided in Section 9.1.22 .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89686] 2017
Eligible subjects will receive ope n-label infusio ns of vedo lizumab IV 300 mg at Weeks 0 and 2, 
and will be assessed for clinical response (defined as a ≥70 point decrease in CDAI score fro m 
baseline [Week 0] at Week 6). Subjects with clinical response at Week 6 will be rando mized at a 
2:[ADDRESS_89687] ions of vedo lizumab SC 108 mg or placebo SC Q2W, beginning 
at Week 6 through Week 50.
Randomization will be stratified by:
Concomitant use of oral corticosteroids.
Clinical remissio n status at Week 6. 
Previous TNF -α antagoni st failure /exposed or concomitant immuno modulator (azathi oprine, 
6-mercaptopurine, or methotrexate) use.
[IP_ADDRESS] Nonr esponders
Subjects who are non responders at Week [ADDRESS_89688] vedol izumab IV infusio n at Week 6. Subjects who achieve 
a clinical response (by [CONTACT_82294] ) at Week [ADDRESS_89689] 
complete the End of Stud y eCRF page.
Subjects who complete the study  will be offered entry  into the OLE study  after com pletion of  the 
Week 52/ET assessment. Week [ADDRESS_89690] dose of 
study  drug f or Week 52 completers/ET.
Subjects at W eek 14 who are responders and are eligible to participate in the OLE will not 
complete an ET visit but complete procedure sas per the Schedule of Study Procedures 
(Appendix 
A). For Week [ADDRESS_89691] OLE vedolizumab SC dose as close 
to Week 14 as possible (preferably wit hin Week 14 ±3 days). If this window is too challenging for 
the sites, dosing wi thin week 14 ±[ADDRESS_89692] ive(ie, maintaining 
trough c oncentration at or above 10 µg/mL) .
Subjects who are discontinued due to disease worsening (after Week 6 )during the Maintenance 
Period will be o ffered entry  into the OLE study .
From  Week 14 on wards , subjects in the Maintenance Phase who are withdrawn fro m the study due 
to need for rescue medications, despi[INVESTIGATOR_82247], will be 
offered entry  into the OLE study . Rescue medicat ions are defined as any new medicat ion or any  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89693] 2017
increase in dose of a baseline medication required to treat new or unresolved CD symptoms (other 
than antidiarrheals for control of chronic diarrhea).
Subjects who are discontinued due to AEs related  to study drug that lead to discontinuation or 
require a surgical intervention for their CD will not be eligible to enroll into the OLE study.
9.3.[ADDRESS_89694] Study 6-month Long-Term Follow-Up Survey
Upon completion of (including OLE nonenroller s from Week 14) or ET from the study, all 
subjects not entering the OLE study will be require d to participate by [CONTACT_57799] a LTFU safety 
survey [ADDRESS_89695] dose of study drug (from the last dose received). 
9.3.6 Unscheduled Visi ts Due to Disease Exacerbation 
Subjects who are seen by [CONTACT_82295] a time point not required by [CONTACT_760] 
(ie, unscheduled visit) due to disease exacerbation will undergo the following: 
!Physical examination. 
!Vital signs assessment. 
!Diary review. 
!Collection of concomitant medications and procedures.
!Collection of AEs and SAEs.
!Clinical chemistry and h ematology, as indicated.
!Partial or complete CDAI. 
!PK sample collection
!  
!Stool sample for fecal calprotectin, if indicated.
!C. difficile , if indicated.
There is no minimum time for rep eat evaluation by [CONTACT_82296] a
subject meets the criteria for disease worsening. In general, however, enough time should be 
provided for clinically meaningful change to occur. 
Property of Take or non-commercial use only and subject to the applicable Terms of UseFFolollolow-w
be compe com
or ET froor ET 
ate by[CONTACT_82297] a tif at a 
n will un will 
medicatdica i
SAEs.AEs.
and hemd he
plete CDlete C
ecoollectlle
oolool sam sll
C. diffC. d
ThereThe
suCCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89696]’s 
participation in the study and the subject should be returned to the care of a physician and standard 
therapi[INVESTIGATOR_82248].
9.[ADDRESS_89697] may be identified but only indirectly. The code 
numbers will be kept secure by [CONTACT_82298].
 
 
.
Property of [COMPANY_005]: For non-comm rcial use only and subject to the applicable Terms of Usebject’s bject’s 
standartanda
sent to aent to 
tyy. The . The
ollected alected
limited amite
the resehe res
ommpletpletmmmm ioi
aw and sand 
e identident ifi
ached hed to
and datand d
 subject subjec
n behalf beha
CCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89698] 2017
10.0 PRETREATMENT EVENTS (PTE) ADVERSE EVENTS (AE) AND PRODUCT 
COMPLAINTS (PC)
10.[ADDRESS_89699] who has 
signed inform ed consent to participate in a study  but pri or to administration of any study  
medicat ion; it does not necessarily have to have a causal relat ionship with study  parti cipat ion.
10.1.[ADDRESS_89700] 
administered a drug; it does not necessarily have to have a causal relat ionship with this treatment.
An AE can therefo re be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug whether or 
not it is considered related to the drug.
In addit ion, drug -device AEs related to qualit y or malfunct ion will be collected.
10.1.[ADDRESS_89701] finding generally may:
Indicate a new diagnosis or unexpected worsening of a pre- exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions underlying disease should not be considered PTEs or AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by [CONTACT_4168].
PTEs/AEs caused by a study procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (inc luding 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as a PTE(s) or as an AE(s).
Laboratory  values and ECG findings:
Chang es in laboratory values or ECG parameters are only considered to be PTEs or AEs if the y 
are judged to be clinically significant (ie, if some action or intervent ion is required or if the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89702] 2017
investigator judges the change to be bey ond the range of normal physio logic fluctuati on). A 
laboratory  re-test and/or continued monitoring o f an abnormal value are not considered an 
intervent ion. In addit ion, repeated or addit ional noninvasive testing for verificat ion, evaluatio n 
or monitoring of an abnormalit y is not consid ered an intervent ion.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as a PTE or as an AE.
Pre-exist ing condit ions:
Pre-exist ing condit ions (present at the time o f signing of informed consent) are considered 
concurrent medical condit ions and should NOT be recorded as PTEs or AEs. Baseline 
evaluat ions (eg, l aboratory  tests, ECG, X -rays etc.) shoul d NOT be recorded as PTEs unless 
related to study  procedures. However, if the subject experiences a worsening or complication 
of such a concurrent condit ion, the worsening or complicat ion shoul d be recorded 
appropriately  as a PTE (worsening or complicat ionoccurs before start of study medicat ion) or 
an AE (worsening or complicat ion occurs after start of study medicat ion). Investigators should 
ensure that the event term recorded captures the change in the condit ion (eg, “worsening 
of…”).
If a subject has a p re-exist ing epi[INVESTIGATOR_45283] (eg, asthma, epi[INVESTIGATOR_002]) any occurrence of an 
epi[INVESTIGATOR_45284] a PTE/AE if the epi[INVESTIGATOR_45285], serious or 
severe in nature, that is, invest igators should ensure that the AE term recorded capture s the 
change in the condit ion from Baseline (eg “worsening of…”).
If a subject has a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion shoul d only  be captured as a PTE/AE if occurring to a greater 
extent to that which would be expected. Again, investigators should ensure that the AE term 
recorded captures the change in the condit ion (eg, “worsening o f…”).
Worsening of PTEs or AEs:
If the subject experiences a worsening or complicatio n of a PTE after starting administration of 
the study  medicat ion, the worsening or complicat ion should be recorded appropriately as an 
AE. Invest igators should ensure that the AE term recorded captures the change in the condit ion 
(eg, “worsening of…”).
If the subject experiences a worsening or com plicati on of  an AE after any  change in study  
medicat ion, the worsening or complicat ion should be recorded as a new AE. Investigators 
shoul d ensure that the AE term recorded captures the change in the condit ion (eg, “worsening 
of…”).
Change s in severi ty of AEs /Seri ous PTEs:
If the subject experiences changes in severit y of an AE/seri ous PTE, the event should be 
captured once with the maximum severit y recorded.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89703] anned surgeries or procedures:
Prepl anned procedures (surgeries or therapi[INVESTIGATOR_014] ) that were scheduled prior to signing of 
inform ed consent are not considered PTEs or AEs. However, if a preplanned procedure is 
perform ed early  (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the 
worsening of the condit ion should b e captured appropriately as a PTE or an AE. Complicat ions 
resul ting fro m any planned surgery  shoul d be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not b e recorded as PTEs or AEs, but should be documented in the subject’s source 
docum ents. Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):
Insufficient clinical response, efficacy, or pharm acologic act ion, should NOT be recorded as 
an AE. The invest igator must make the dist inction bet ween exacerbation o f pre-exist ing illness 
and lack of therapeutic efficacy.
Overdose:
Cases of overdose with any  medicati on wi thout m anifested si de effe cts are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any 
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
10.1.[ADDRESS_89704] medical o ccurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPI[INVESTIGATOR_39749].
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of th e following:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89705] 2017
Includes any event or synonym described in the [COMPANY_005] Medically  Significant AE List 
(Table 10.a).
Table 10.a [COMPANY_005] Medically Significant AE List 
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_82249] / ventricular fibrillation / ventricular 
tachycardiaAcute liver failure
Anaphy lactic shock
Malignant hypertension Acute renal failure
Convulsive seizure Pulmonary hypertension
Agranulocytosis Pulmonary f ibrosis 
Aplastic anemia Confirmed or suspected endotoxin shock
Toxic epi[INVESTIGATOR_194]/Stevens -Johnson syndrome Confirmed or suspected transmission of infectious agent by a 
medicinal product
Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and fo llowed up in the same manner (see Sections 10.2.2 and 10.3).
10.1.[ADDRESS_89706] Adverse Event (serious or non -serious) is one of scientific and medical concern 
specific to the compound or program, for which ongoing monitoring and rapid communicati on by 
[CONTACT_82299]. Such events may require further invest igation in 
order to characterize and understand them and would be described in protocols and instructions 
provi ded for investigators as to how and w hen they  should be reported to [COMPANY_005]. Refer to 
Secti on10.2.1.[ADDRESS_89707] AE reporting.
10.1.6 Severity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as follows:
Mild: The event is transient and easily tolerated by [CONTACT_423].
Moderate: The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activi ties.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89708] 2017
10.1.7 Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of t he drug), or for which possible involvement of the drug cannot be 
ruled out, although factors other than the drug, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by [CONTACT_1604], such as underlying diseases, complications, 
concomitant drugs and concurrent treatments.
10.1.8 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all PTEs and AEs.
The rel ationship should be assessed as Related if the invest igator considers that there is a 
reasonable possibilit y that an event is due to a study procedure. Otherwise , the relat ionship should 
be assessed as Not Related. 
10.1.9 Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by  [CONTACT_14426]/or physician.
10.1.10 Stop Date 
The stop date of the AE/PTE is the date at which the subject rec overed, the event resolved but with 
sequelae or the subject died.
10.1.11 Frequency 
Epi[INVESTIGATOR_39751] c AEs/PTE (eg, vomit ing) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.12 Action Concerning Study Medication 
Drug withdrawn –a study  medicat ion is stopped due to the particular AE.
Dose not changed –the particular AE did not require stoppi[INVESTIGATOR_007] a study  medicat ion.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not Applicable –a study  medicat ion was stopped for a reason other than the particular AE eg, 
the study  has been terminated, the subject died, dosing wit h study  medicat ion was already  
stopped before the onset of the AE.
Dose Interrupted –the dose was inte rrupted due to the particular AE.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89709] 2017
10.1.13 Outcome
Recovered/Resolved –Subject returned to first assessment status with respect to the AE/PTE
Recovering/Reso lving –the intensit y is lowered by  1or more stages: the diagnosis or 
signs/symptom s has almost di sappeare d; the abnormal laboratory  value improved, but has not 
returned to the normal range or to baseline; the subject died from a cause other than the 
particular AE/PTE with the condit ion rem aining “recovering/reso lving”.
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, si gns/ symptom s or laboratory  value on the last day  of the observed 
study  period has got worse than when it started; is an irreversible congenital anomaly; the 
subject died fro m another cause with the particular AE/PTE state remaining “Not 
recovered/not resolved”.
Reso lved with sequelae –the subject recovered from an acute AE/PTE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but w ith 
some persisting paresis.
Fatal  –the AEs/PTEs which are considered as the cause of death. 
Unknown –the course of the AE/PTE cannot be followed up due to hospi[INVESTIGATOR_1670]’s participation in the study .
10.1.[ADDRESS_89710] and/or device (eg, prefilled 
syringe).
An invest igator who is made aware of or ident ifies a potential PC should immediately report the 
event to [COMPANY_005] in accordance with the contact [CONTACT_82300]. Whenever possible, the 
associ ated product should be maintained in accordance with the instructions pending further 
guidance fr om a [COMPANY_005] representative. Refer to the appropriate study  manual  provided separately 
for addi tional information (depending on local regulat ions).
10.2 Procedures
10.2.1 Collection and Reporting of AEs
[IP_ADDRESS] PTE and AE Collection Period
Start of AE collection: AEs must be c ollected fro m start of study  medicat ion administration. 
End of AE collection: AEs must be collected for [ADDRESS_89711] administered study medicat ion or until 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89712] administered study 
medication (enrollment). Routine collection of AEs w ill continue until [ADDRESS_89713] dose.
[IP_ADDRESS] PTE and AE Reporting
At each study visit, the investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing a 
serious PTE must be monitored un til the symptoms subside and any clinically relevant changes in 
laboratory values have returned to baseline or there is a satisfactory explanation for the change. 
Non-serious PTEs, related or unrelated to the st udy procedure, need not to be followed-up for the 
purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medication 
or not, must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to baseline or un til there is a satisfactory explanation for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the eCRF, 
whether or not the investigator concludes that the event is related to the drug treatment. The 
following information will be documented for each event:
1. Event term.
2. Start and stop date (and time, if deemed directly related to the study drug administration).
3. Severity.
4. Investigator’s opi[INVESTIGATOR_82250] p between the event and administration of study 
medication(s) (related or not related) (not completed for PTEs).
5. Investigator’s opi[INVESTIGATOR_82250] p to study procedure(s), including the details of 
the suspected procedure.
6. Action concerning study medication (not applicable for PTEs).
7. Outcome of event.
8. Seriousness.
Several patient-reported outcomes measures will be used in this study (eg, IBDQ, EQ5D, 
). They will not be used as a primary means to collect AEs. However, should the 
investigator become aware of a potential AE through the information collected with this 
instrument, proper follow-up with the subject for medical evaluation should be undertaken. 
Through this follow-up, if it is determined that an AE not previously reported has been identified, 
normal reporting requiremen ts should be applied.
Property o keda: For non-commercial use only and subject to the applicable Terms of Useoseose..
occurredoccurre
ay y be askbe a
ects expets exp
cally relelly re
planatilanati o
d not to bnot t
d with thwith t
d any clinany cl
re is a sais a s
mented innted i
e event ievent 
each evach ev
eemed diemed 
he causae cau
or not renot 
ion of thn of t
rocedurecedu
cerning serning
e ofof eveff
ousnesusne
veral patal pa
investinv
insCCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89714] 2017
[IP_ADDRESS] Adverse Event Collection Involving Medically Anticipated Clinical Events 
CD is associated with certain characterist ic signs and symptoms, including diarrhea and abdomina l 
pain, that m ay be present at baseline and persist or fluctuate based on the individual subject’s 
disease history  during the course of the study. These signs and symptoms are considered medically 
anticipated clinical events for the condit ion under study  and will  not be collected as AEs. These 
characterist ics of diseas e act ivity will be regularly captured i n the CDAI score and will be 
reviewed by  [CONTACT_28826] y Moni toring Board (DSMB).
Exacerbat ions of disease act ivity (eg, increase in the daily amount of abdo minal pain beyo nd the 
subject ’s normal fluctuation, new sign s or symptoms of CD) will be collected as AEs and reported 
according to regulatory  reporting requi rements. 
Extra -intestinal manifestations of the subject’s disease (eg, arthralgia, arthrit is, uveit is) that 
develop or worsen during the study  are consi dered AEs. 
[IP_ADDRESS] Special Interest AE Reporting
If this special interest AE , whi ch occurs during the treatment period or the fo llow-up peri od, is 
considered to be clinically significant based on the criteria below, it should be recor ded in the specia l 
interest AE eCR F or an SAE Form. The applicable form shoul d be co mpleted and reported to the 
SAE reporting contact [CONTACT_82301] 1.1within 24 hours.
Hypersensitivity Reactions (Including Injection Site Reactions).
Current ly, the re is no evi dence to support the routi ne prophylactic administration of premedication 
(eg, antihistamines, corticosteroids) to subjects receiving vedo lizumab; hence such premedicat ions 
are unlikely to be necessary  or beneficial. At the discretion of the in vestigator, however, subjects 
may be administered premedicat ion prior to any study drug administration. Corticosteroids, if given 
as a prem edicat ion, should be limited to the day  of administrati on. 
Vedolizumab IV should be administered by a HCP prepared to m anage hypersensit ivity react ions 
including anaphylaxis, if they occur. Appropriate mo nitoring and m edical  support m easure shoul d 
be available for immediate use. Subjects should be observed for [ADDRESS_89715] ions including 
anaphylaxis, if they occur. Appropriate monitoring and medical support measure should be available 
for immediate use. 
Subjects and caregivers will be instructed to report the development of rash, hives, pruritus, flushing, 
urticaria, injections site pain, redness and/or swelling, etc. that may represent an 
administration -related reacti on (ie, inject ion-site reacti on or infusi on-related reacti on) to study  
medicat ion. Subjects will be asked to report administration -related AEs to the si tes immediately  as 
they are experienced or after having received appropriate medical care. Appropriate treatment and 
follow-up will be determined by  [CONTACT_17062]. If si gns or symptom s of an administration -related 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89716] ion, study  
drug administration may  be reinit iated (with appropriat e premedicat ion and invest igator 
supervisio n) at the discret ion of the investigator. Subjects with a severe or serious 
administration -related reacti on (eg, shortness of breath, wheezing, stridor, angioedema, 
life-threatening change in vital signs, severe i njection site reactions) must be withdrawn fro m the 
study  (see the appropri ate Study  Manual ). 
In all cases of administration -related reacti on, the medical mo nitor must be informed as soon as 
practi cal. The disposit ion of subjects with less severe administ ration-related reacti ons shoul d be 
discussed wi th the m edical m onitor.
Serious Infections 
Subjects will be mo nitored for si gns and symptoms of infect ion and for lymphopenia during the 
study . Subjects with signs and symptoms suggestive of infect ions, inclu ding GI infect ions, will be 
treated as clinically indicated. Interventions may include ant ibiotic treatment, if appropriate and/or 
discontinuat ion of conco mitant immuno modulators. Bl ood, sputum , urine, and/or stool cultures 
shoul d be obtained as appropriat e for the detection and diagnosis of infection. Withho lding or 
terminating study  drug administrati on m ay be considered as described in Sect ion7.4.
Malignancy 
All cases of malignancies that are detected during the study will be reported as AEs. Local medica l 
practi ces for the management of malignances will apply. Subjects with history  of malignancy 
(except for specific cancers) or at high risk for malignancy will be excluded from the study per the 
exclusio n criteria. 
Other 
Other special interest AEs include liver injury and PML, which are discussed in Sections 10.2.3
and 11.2.1 respectively.
10.2.2 Collection and Reporting of SAE s
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A [COMPANY_005] SAE eCRF or Form must be completed, in English, and signed by [CONTACT_39808] [ADDRESS_89717] onset or notif ication of  the event. The informat ion shoul d 
be co mpleted as fully as possible but con tain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study medicat ion(s)
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89718] 2017
Causalit y assessment.
The SAE eCRF should be co mpleted wi thin [ADDRESS_89719] ion period should be 
reported to the sponsor if considered r elated to study  parti cipat ion.
Reporting of Serious PTEs will fo llow the procedure described for SAEs.
*Note: For Japanese sites, the invest igator should report the detailed paper SAE report provided by 
[CONTACT_82302] o f initial inform ation. Addit ional 
detailed fo llow-up data surrounding the serious adverse event that becomes available fo llowing 
the init ial report should be communicated through the same channels as outlined above. 
10.2.[ADDRESS_89720] elevated >3 ×ULN on [ADDRESS_89721] >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event shoul d be recorded as an SAE and reported 
as per Secti on 10.2.[ADDRESS_89722] details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute liver disease or medical  history /concurrent m edical  condi tions. Fo llow-up laboratory  
tests as described in Sect ion 9.1.[ADDRESS_89723] be completed and transmitted with the [COMPANY_005] SAE Form (as per Section 10.2.2 )
.
10.[ADDRESS_89724] report becomes available at a later date, the 
inves tigator shoul d com plete a follow -up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt. Copi[INVESTIGATOR_1672] 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) s hould be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.3.[ADDRESS_89725] ions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory  authori ties, including the European 
Medicines Agency , invest igators and IRBs or IECs, as applicable, in accordance with nat ional 
regul ations in the countries where the study  is conducted. Relat ive to the first awareness of the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89726] 2017
event by/or further provisio n to the sponsor or sponsor’s designee, S[LOCATION_003]Rs will be submitt ed to 
the regulatory authorit ies as expedited report within [ADDRESS_89727] a copy of all expedited reports to his 
or her IRB or IEC in accordance with national regulat ions.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89728] (DSMB) independe nt from the sponsor will be established to 
review unblinded safet y data fro m this study  on a regul ar basis and to m ake appropri ate 
recommendat ions regarding the safe conduct of the study . 
A detailed charter will outline the activit ies and scope of the DSM B (eg, ty pe of  data revi ewed, 
frequency  of meetings and location of meet ings) . 
11.2 Adjudication Committee 
A PML Independent Adjudicat ion Committee (IAC) will be implemented for this study. The PML 
IAC will consist of a panel of leading PML experts, including a neuro logist, neuroradio logist, and 
a virologist. 
11.2.1 Risk Minimization Action Plan for PML (RAMP Program)
Natalizumab (TYSABRI), another integrin receptor antagonist, has been associated with 
progressive mult ifocal leukoencephalopathy  (PML), a rare and oft en fatal opportunistic infect ion 
of the CNS . PML is caused by  [CONTACT_82303] t ypi[INVESTIGATOR_82251] [40,41] . Natalizumab is a pan - α4integrin antagonist that binds to both the 
α4β1and α 4β7integrins and inhibit s cellular adhesion to VCAM -1 and MAdCAM -1 [42,43] . In 
contrast, vedolizumab binds to the α 4β7integrin only [29]and inhibits adhesio n to MAdCAM -1, 
but not VCAM -1. Al though no cases of PML have been reported in clinical trials wit h 
vedo lizumab to date, a risk of PML cannot be ruled out.
To address the theoretical risk o f the development of PML in subjects treated with vedo lizumab, 
the sponsor, with inp ut from renowned PML experts, has developed a Risk Minimization Act ion 
Plan for PML, the RAMP. The complete description of the RAMP program, including materials 
and instructions for its implementation and mo nitoring, is included in the appropriate Study  
Manual. 
The RAMP is focused on early  clinical detecti on and management of that specific safet y risk, 
including the discont inuat ion of study  drug, if applicable. Subjects are assessed for signs and 
symptoms of PML prior to the administration of each dose of study  drug using a PML subject ive 
symptom  checklist. Subj ects wi th a posi tive PML subjective symptom checklist at any  time after 
enrollment in a vedolizumab clinical study will be evaluated according to a prespecified algorithm 
(the PML Case Evaluat ion Alg orithm). The respective dose of study drug will be withheld unt il the 
evaluat ion is co mplete and results are available. Subsequent doses of study  will be administered 
only if the possibilit y of PML is definit ively  excluded, as described in the RAMP algorit hm. An 
IAC has been stabled as part of the RAMP program to review new neuro logical signs and 
symptoms potentially  consistent wi th PML, and will provide input regarding subject evaluat ion 
and management as defined in the IAC charter. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89729] 2017
To ensure success of t he RAMP program, site personnel will be trained to recognize the features of 
PML, and subjects will be trained to report specific neurological signs and symptoms without 
delay. Educati onal materi als for teaching site personnel and subjects about PML and th e RAMP 
procedures will be distributed to all sit es and are included in the appropriate Study  Manual. Forma l 
teaching and training will be performed for site personnel prior to the start of the study . Subjects 
will receive training and educat ional materi alsprior to receiving treatm ent. The informed consent 
form will contain specific informat ion on the hypothetical risk of PML. Any documented case of 
PML will be reported as an SAE, regardless of whether hospi[INVESTIGATOR_39753].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89730] ionary 
for Regul atory  Activit ies (MedDRA). Drugs will be coded usi ng theWorld Heal th Organizat ion 
Drug Dict ionary.
12.[ADDRESS_89731] be completed in English. Data are transcribed directly onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_1748] (or designees) and will be answered b y the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change.
The principal invest igator mus t review the eCRFs for completeness and accuracy  and must si gn 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
eCRFs will be revi ewed f or com pleteness and acceptabilit y at the study  site during peri odic visi ts 
by [CONTACT_39810]. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospi[INVESTIGATOR_4077]. T he completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the spo nsor.
12.[ADDRESS_89732] igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any  source 
docum entati on printed on degradable thermal sensitive paper should be photocopi[INVESTIGATOR_47355] h the original in the subject’s chart to ensure long term legibilit y. Furtherm ore, 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89733] 2017
International Conferen ce on Harm onisati on (ICH) E6 Secti on 4.9.5 requi res the investigator to 
retain essential documents specified in ICH E6 (Section 8) until at least [ADDRESS_89734] igation is discont inued and 
regul atory  authori ties are notified. In addit ion, ICH E6 Secti on4.9.5 states that the study  records 
shoul d be retained unt il an amount of time specif ied by [CONTACT_63227] a 
time specified in the Clinical Study  Site Agreement between the investigator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator sho uld contact [CONTACT_4182] m the sponsor before disposing of any 
such documents.
2.The fo llowing procedure is applied for Japanese sit e only .
The investigat or and the head of the inst itutionagree to keep the records stipulated in Section 12.1
and those documents that include (but are not limit ed to) the study -specific documents, the 
ident ificat ion log of all part icipating subjects, medical records, temporary media such as thermal 
sensit ive paper, source worksheets, all original signed and dated informed consent forms, subject 
authori zation forms regarding the use of personal health informat ion (if separate from the 
inform ed consent forms), electronic copy  of eCRFs, incl uding the audi t trail, and de tailed records 
of drug disposi tion to enable evaluat ions or audits fro m regulatory  authori ties, the sponsor or its 
designees. Any source documentation printed on degradable thermal sensit ive paper should be 
photocopi [INVESTIGATOR_82252]’s chart to ensure long term 
legibilit y. Furtherm ore, ICH E6 Secti on 4.9.[ADDRESS_89735] igator and the head o f the 
institution to retain essent ial documents specified in ICH E6 (Section 8) until at least [ADDRESS_89736] igator and/or the head of the 
institution and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator and the head of the institution should contact [CONTACT_4182] m the 
sponsor before disposing of any  such documents.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89737] 2017
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized prior to database lock and 
unblinding of subjects’ treatment assignments. This document will provide further details 
regarding the definit ion of ana lysis variables and analysis methodology  to address all study  
objectives.
A blinded data review meeting will be conducted prior to unblinding of subjects’ treatment 
assignment and database lock. This review will assess the accuracy and completeness of the study 
database, subject evaluabilit y, and appropriateness of the planned statist ical methods.
13.1.[ADDRESS_89738] 1 dose of study  
drug. Subjects in this set will be analyzed accordin g to the treatment they  were randomized to 
receive.
The per protocol (PP) populat ion is a subset of the ITTpopulat ion. The PP populat ion consists of 
all subjects who do not vio late the terms of the protocol in a way  that woul d impact the study  
output si gnificant ly. All decisio ns to exclude subjects for the PPpopulation dataset will be made 
prior to the unblinding of the study . Analyses using the PP populat ion may be provided as a 
sensit ivity analysis.
The Safet y Analysis Set will include all subjects who receive at least [ADDRESS_89739] of descript ivestatistics (number of 
subjects, mean, standard deviat ion, minimum, median, and maximum). For categorical variables, 
the summary  will consist of number and percentage of subjects in each category .
Medical history and concurrent medical condit ions will be s ummari zed by [CONTACT_39812]. Medicat ion history  and conco mitant medicat ions will be summarized by [CONTACT_39813].
13.1.[ADDRESS_89740] 
secondary  endpoint of enhanced clinical response will only  be perform ed if the primary  endpoint, 
proporti on of  subjects wi th clinical  remissi on at Week 52 , is stati stically significant. The second 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89741] 2017
13.1.7 Safety Analysis
Safety analysis will be performed using the Safety Analysis Set. No statistical inference will be 
made for safety analyses.
The number and percentage of subjects with TEAEs (defined as any AEs, regardless of 
relationship to study drug), AESIs (ie, serious infections, including opportunistic infection such as 
PML, malignancies, liver injury, infusion reactions, injection site reactions), and SAEs which 
occur on or after the first dose date and up to [ADDRESS_89742] data will be presented in data listings.
13.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
Property of [COMPANY_005]: For non-commercial use only and subject tot. No statNo st
fined as fined a
ons, incluns, inc
s, injectinjec i
weeks aweek
up to the to th
Organ COrgan
p to studp to stu
r treatmetreat
re adjustadju
ical labocal lab
edlydlyabnabyy
ies ofs of TETff
ase ebetwbet
the firstthe fir
m the LTm the L
hift in Ehift in 
aminataminat io
13.213.
NUseCCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89743] 2017
13.3 Determination of Sample Size
Assuming a clinical remissio n rate of 38% for vedolizumab and 22% for placebo at Week 52, a 
sample size of 258 subjects in the vedo lizumab group and 129 subjects in the placebo group will 
provi de 90% power at 2 -sided 0.05 l evel of significance. To ensure a randomized sample size of 
387 subjects, assuming 47% of the subjects entering induction will achieve clinical response at 
Week 6, approximately  824 subjects will need t o be enrolled into the study .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89744] itution guarantee access to source documents by  [CONTACT_3210] i ts 
designee (contract research organi zation) and by [CONTACT_4186].
All aspects of the study and its documentation will be subject to review by [CONTACT_36613] 
(as long as blinding is not jeopardized), including but not limited to the Invest igator’s Binder, 
study  medicat ion, subject m edical records, informed consent documentation, documentation of 
subject authorizat ion to use personal healt h information (if separate fro m the inform ed consent 
forms), and review o f eCRFs and associated source documents. It is important that the invest igator 
and other study  personnel are available during the mo nitoring visits and that sufficient time is 
devoted to the process.
14.[ADDRESS_89745] to study  subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course ofaction. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul dnotify the sponsor or its designee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessmen t. 
Significant protocol  deviat ions will be entered into the eCRF, which is reviewed by [CONTACT_82304].
The procedure below applies to Japanese sites only.
The invest igator can deviate and change from the protocol for any medically unavo idable reason, 
for example, to eliminate an immediate hazard to study subjects, without a prior written agreement 
with the sponsor or a prior approval fro m IRB. In the event of a deviat ion or change, the 
investigator should notify  the sponsor and the head of t he study  site of the deviat ion or change as 
well as its reason in a written form, and then retain a copy of the written form. When necessary, the 
investigator may  consul t and agree wi th the sponsor on a protocol amendment. If the protocol 
amendment i s appr opriate, the am endment proposal should be submitted to the head of the study  
site as soon as possible and an approval from IRB should be obtained. The invest igator should 
docum ent all  protocol  deviat ions.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89746] the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by [CONTACT_17513], including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contact[CONTACT_4190] a regulatory  body , the sponsor should be notifi ed 
immediately . The invest igator and inst itution guarantee access for qualit y assurance auditors to all 
study  docum ents as described in Section 14.1.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89747] for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduc t 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The principles of Helsinki  are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/l ocal requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , writtennotification regarding his or her abstinence fro m 
voting must also be obtained. Those Americas sites unwilling to provide names and tit les of all 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or com parable number assigned by  [CONTACT_9930].
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Br ochure, a copy  of 
the informed consent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other documents required by [CONTACT_1763], must be submitted to a 
central  or local IRB or IEC for approval. The I RB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or study specific 
screening activit y). The IRB or IEC approval must refer to the study  by [CONTACT_45343], 
number, and versio n date; ident ify versio ns of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will ship drug and notify site once the s ponsor 
has confirmed the adequacy  of site regul atory  documentati on and, when applicable, the sponsor 
has received permissio n from competent authorit y to begin the trial. Unt il the site receives 
notification no protocol act ivities, including screening may o ccur.
Sites m ust adhere to all requirements stipulated by  [CONTACT_4195]. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  [CONTACT_82305], local safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  [CONTACT_39820], and submissio n of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals an d relevant docum entati on for these i tems m ust be provi ded to the 
sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by [CONTACT_4197].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89748] authorization form (if 
applicable), and subject information sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclosures of the subject’s personal and personal health information for purposes of 
conducting the study. The informed consent form and the subject information sheet (if applicable) 
further explain the nature of the study, its objectives , and potential risks and benefits, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any time without giving a reason and 
without prejudice to his or her further medical care.
The investigator is responsible for the preparation, content, and IRB or IEC approval of the 
informed consent form and if applicable, the subject authorization form. The informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) must 
be approved by [CONTACT_39821].
The informed consent form, subject authorization form (if applicable), and subject information 
sheet (if applicable) must be written in a language fully comprehensible to the prospective subject. 
It is the responsibility of the investigator to explain the detailed elements of the informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by [CONTACT_4186]. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally acceptable representative may 
provide such cons ent for the subject in accordance with applicable laws and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will participate in 
the study, then the informed consent form and s ubject authorization form (if applicable) must be 
signed and dated by [CONTACT_423], or the subject’s legally acceptable representative, at the time of 
consent and prior to the subject entering into the study. The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpoint ink. The investigator must also sign and date the informed consent 
form and subject authorization (if applicable) at the time of consent and prior to subject entering 
into the study; however, the sponsor may allow a designee of the investigator to sign to the extent 
permitted by [CONTACT_1289].
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject information sheet (if applicable) will be stored in the investigator’s site file. The Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Used in the in th
with allwith a
on nfoformrm
d and perand pe
rmatatioionn
matmatioion shn 
ks and bs and 
etail the tail th
ytime wiime w
ent, and nt, and
authorizuthori
nd subjecsubje
onsor prnsor p
izatatioion nf
languagangua
ator to exor to e
f applicaapplic
given in ven in
by [CONTACT_82306] I
d consenconse
or the suthe s
subject’subject
t details detail
e subjece subje
then thehen th
and datend dat
ent and nt an
cceptableceptab
using using b
foform
inCCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89749]’s 
medical record. Copi[INVESTIGATOR_1681], the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shal l be given to the subject.
All revised informed consent forms must be reviewed and signed by [CONTACT_39822]’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
15.[ADDRESS_89750]’s right to protection
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by [CONTACT_39823], limited subj ect attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sp onsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospi[INVESTIGATOR_45291] a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 15.2).
Copi [INVESTIGATOR_39757] (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
15.[ADDRESS_89751] igators or to regulatory  agencies, except as required by  
[CONTACT_4201]. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessibl e websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  [CONTACT_3170]) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89752] be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
15.4.2 Clinical Trial Registration
In orde r to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, [COMPANY_005] will, at a minimum register 
intervent ional clinical trials it sponsors anywhere in the world on Clini calTri als.gov or other 
publicly  accessible websites before start of study , as defined in [COMPANY_005] Policy/Standard. [COMPANY_005] 
contact [CONTACT_4203], along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be register ed and available for public viewing. 
For some registries, [COMPANY_005] will assist callers in lo cating trial sites closest to their ho mes by 
[CONTACT_39824], address, and phone number to the callers request ing trial 
inform ation. Once subjects re ceive invest igator contact [CONTACT_4203], they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor. 
Any invest igator who objects to [COMPANY_005] providing this informat ion to callers must provide [COMPANY_005] 
with a wri tten noti ce request ing that their informat ion not be liste d on the registry  site. 
15.4.[ADDRESS_89753] the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by [CONTACT_39825]/Standard, applicable laws and/or regulat ions.
15.[ADDRESS_89754] is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the Clinical Study  Site Agreement regarding the sponsor’s policy on subject 
compensat ion and treatment for injury. If the investigator has questions regarding this po licy, he or 
she should contact [CONTACT_4209]’s designee.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89755] 2017
16.0 REFERENCES
1. Loftus EV, Jr. Clinical epi[INVESTIGATOR_82253]: Incidence, prevalence, 
and environmental influences. Gastroenterology  2004;126(6):[ADDRESS_89756] -Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of 
inflammatory  bowel  disease across Europe: is there a difference between north and south? 
Results of the European Collaborative Study  on Inflammatory  Bowel  Disease (EC -IBD). 
Gut 1996;39(5):690-7.
3. Trallori G, Palli D, Saieva C, Bardazzi G, Bonanomi AG, d'Albasio G, et al. A 
popul ation-based study  of inflammatory  bowel  disease in Florence over 15 years (1978 -92). 
Scand J Gastroenterol 1996;31(9):892 -9.
4. Asakura K, Nishi waki  Y, Inoue N, Hibi  T, Watanabe M, Takebayashi T. Prevalence of 
ulcerat ive co litis and Crohn's disease in Japan. J Gastroenterol 2009;44(7):659 -65.
5. Kakkar A, Wasan SK, Farraye FA. Targeting mucosal healing in Crohn's disease. 
Gastroenterol Hepatol (N Y) 2011;7(6):374- 80.
6. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory  bowel  
disease: results fro m a Norwegi an popul ation-based cohort. Gastroenterology  
2007;133(2):412 -22.
7. Ferrante M, Colo mbel JF, Sandborn WJ, Reinisch W, Mant zaris GJ, Kornbluth A, et al. 
Validat ion of endoscopic activit y scores in pat ients with Crohn's disease based on a post hoc 
analysis of data fro m SONIC. Gastroenterology  2013;145(5):978 -86 e5.
8. Rutgeerts P, Diamo nd RH, Bala M, Olson A, Lichtenstein GR, B ao W, et al. Scheduled 
maintenance treatment with infliximab is superior to epi[INVESTIGATOR_82254]'s disease. Gastrointest Endosc 2006;63(3):433 -42; 
quiz 64.
9. Daperno M, D'Haens G, Van Assche G, Bae rt F, Bulo is P, Maunoury V, et al. Development 
and validat ion of a new, simplified endoscopic act ivity score for Crohn's disease: the 
SES-CD. Gastrointest Endosc 2004;60(4):[ADDRESS_89757] ice. Dig Liver Dis 2013;45(12):[ADDRESS_89758] WR, Kern F, Jr., et al. National 
Cooperative Crohn's Disease Study : resul ts of drug treat ment. Gastroenterology  1979;77(4 
Pt 2):847 -69.
12. Akobeng AK, Gardener E. Oral 5 -aminosalicylic acid for maintenance of medically -induced 
remission in Crohn's Disease. Cochrane Database Sy st Rev 2005(1):CD003715.
13. Kandiel A, Fraser AG, Korelitz BI, Bre nsinger C, Lewis JD. Increased risk of lymphoma 
among inflammatory  bowel disease pat ients treated with azathioprine and 6 -mercaptopurine. 
Gut 2005;54(8):1121-5.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89759] 2017
14. Remicade (infliximab) [ADDRESS_89760] Characteristics. Leiden, The Netherlands: Janssen Bio logics B.V., [ADDRESS_89761] 2013.
15. Humira (adalimumab) inject ion, for subcutaneous use. Full Prescribing Informat ion. North 
Chicago, IL: [COMPANY_013] Inc., Revised May 2013.
16. Cimzia (certolizumab pego l) for inject ion, for subcutaneous use. Prescribing Informat ion. 
Smyrna, GA: UCB, Revised October 2013.
17. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. 
Maintenance infliximab for Crohn's disease: the ACCENT I randomise d trial. Lancet 
2002;359(9317):1541-9.
18. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. 
Adalimumab for maintenance of clinical response and remissio n in pat ients with Crohn's 
disease: the CHARM trial. Gastroenterology  2007;132(1):52 -65.
19. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. 
Certolizumab pego l for the treatment of Crohn's disease. N Engl J Med 2007;357(3):228 -38.
20. Schreiber S, Khaliq -Kareemi M, Lawrance IC, Thomsen OO, Hanauer S B, McColm J, et al. 
Maintenance therapy  with certolizumab pego l for Crohn's disease. New Engl J Med 
2007;357(3):239 -50.
21. Keane J, Gershon S, Wise RP, Mirabile -Levens E, Kasznica J, Schwieterman WD, et al. 
Tuberculosis associated with infliximab, a tumor necrosis factor alpha -neutralizing agent. N 
Engl J Med 2001;345(15):1098-104.
22. Colombel JF, Loftus EV, Jr., Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The 
safet y profile of infliximab in pat ients with Crohn's di sease: the May o clinic experien ce in 
500 pati ents. Gastroenterology  2004;126(1):19 -31.
23. Tysabri  (natalizumab) inject ion. Full Prescribing Informat ion. Cambridge, MA: Biogen Idec 
Inc., Revised March 2014.
24. Stenson WF. Inflammatory  Bowel  Disease. In: Yamada T, Alpers DH, Laine L, Ow yang C, 
Powell DW, editors. Textbook of Gastroenterology. 3rd ed. Philadelphia, PA: Lippi[INVESTIGATOR_32199] & Wilkins; 1999, p. 1775 -839.
25. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocy te trafficking and 
regional immuni ty. Adv Immunol  1999; 72:209 -53.
26. Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commit ment. 
Immunol Rev 2005;206:100-13.
27. Briskin M, Winsor -Hines D, Shyjan A, Cochran N, Bloom S, Wilso n J, et al. Human 
mucosal addressin cell adhesio n mo lecule-[ADDRESS_89762] and 
associ ated lymphoi d tissue. Am J Pathol 1997;151(1):97 -110.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89763] 2017
28. Erle DJ, Briskin MJ, Butcher EC, Garcia -Pardo A, Lazarovits AI, Tidswell M. Expressio n 
and function of the MAdCAM -1 receptor, integrin a lpha 4 beta 7, on human leukocy tes. 
Immuno 1994;153(2):517-28.
29. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificit y and 
select ive antagonism o f vedo lizumab, an anti -alpha4beta7 integrin therapeut ic antibody in 
development for inflammatory  bowel  diseases. J Pharmaco l Exp Ther 2009;330(3):864-75.
30. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colo mbel JF, Sandborn WJ, et al. 
Vedolizumab as induct ion and maintenance therapy for ulcerative co litis. N Engl J Med 
2013;369(8):[ADDRESS_89764] ion and maintenance therapy for Crohn's disease. N Engl J Med 
2013;369(8):[ADDRESS_89765] ion therapy  for pati ents wi th Crohn's disease and prior anti -tumour necrosi s factor 
antagonist failure: a randomised, placebo -controlled, double -blind, mult icentre trial. Journal 
of Crohn's and Co litis 2013;7(Suppl. 1):Pages S5 –S6. 8th Congress of the European Crohn's 
and Co litis Organisat ion.
33. Schellekens H. Factors influencing the immunogenicit y of therapeutic proteins. Nephro l 
Dial Transplant 2005;[ADDRESS_89766] 6:vi3 -
9.
34. Porter S. Human immune response to recombinant human prot eins. J Pharm Sci 
2001;90(1):1 -11.
35. Sipponen T, Karkkainen P, Savilaht i E, Kolho KL, Nuutinen H, Turunen U, et al. Correlat ion 
of faecal  calprotectin and l actof errin wi th an endoscopic score for Crohn's disease and 
histol ogical findings. Aliment Pharmac ol Ther 2008;28(10):[ADDRESS_89767] WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease act ivity 
index. National Cooperative Crohn's Disease Study. Gastroenterology  1976;70(3):439 -44.
37. Irvine EJ. Development and subsequent refine ment of the inflammatory  bowel  disease 
questionnaire: a qualit y-of-life instrument for adult patients with inflammatory bowel 
disease. J Pedi atr Gastroenterol  Nutr 1999;28(4):S23 -7.
38. Konig HH, Ul shofer A, Gregor M, von Tirpi[INVESTIGATOR_7316] C, Reinshagen M, Adler G, et al. Validation 
of the EuroQol  quest ionnaire in pat ients with inflammatory  bowel  disease. Eur J 
Gastroenterol Hepatol 2002;14(11):[ADDRESS_89768] ivity impairment questionnaire in Crohn's disease. Clin Ther 
2008;30(2):393 -404.
40. Major EO. Progressive m ultifocal leukoencephalo pathy  in pat ients on immuno modulatory  
therapi [INVESTIGATOR_014]. Annu Rev Med 2010;61:35 -47.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89769] 2017
41. Steiner I, Berger JR. Update on progre ssive mult ifocal  leukoencephalopathy . Curr Neurol  
Neurosci Rep 2012;12(6):[ADDRESS_89770] ion and maintenance therapy  for Crohn's di sease. N Engl  J Med 
2005;353(18):1 912-25.
43. TYSABRI (natalizumab) injection. Full Prescribing Information. Cambridge, MA: Biogen 
Idec Inc., Revised June 2013.
44. Vitali R, Stronati  L, Negroni  A, Di  Nardo G, Pi [INVESTIGATOR_82255] M, del  Giudice E, et al . Fecal 
HMGB1 is a novel marker of intestina l mucosal  inflammat ion in pediatric inflammatory  
bowel  disease. Am J Gastroenterol 2011;106(11):2029 -
40.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89771] 2017
Appendix A Schedule of Study Procedures: Screening, Induction and Nonresponders 
Study Procedure ScreeningInduction
Open Label Treatment 
PeriodInduction 
ObservationWeek 6 Nonresponders
Open Label Treatment Period
Days -28 to 
-1Week 0 (a)
Day 1Week 2
Day 15
(±2 days)Week 6a (b)
Day 43
(-5 days)Week 6b (b)
Day 43
(+3 days)Week 6b
Day 43
(+3 days)Pre-Week 14
Day 92
(+4 days)Week 14 (t)
Day 99
(±3 days)
OLE Nonenroller OLE Enroller
Clinic Visit Number 1 2 3 4 5 NR5 PW14 NR6 NR6
Informed consent X
Demographics X
Tobacco use X
Medical and CD history X
Prior therapi[INVESTIGATOR_81626] X
Physical examination (c) X X X X X X X
Vital signs (d) X X X X X X X
PML checklist (e) X X X X X X X
PML wallet card X
Diary instruction X
Diary review (f) X X X X X X
Concomitant medications and procedures (g)XXX X
X X X
12-lead ECG X
TB screening (i) X
Vedolizumab IV OL Dosing (j) X X X
Footnotes are on last table page.
Property of [COMPANY_005]: n-commercial use only subject to the applicable Terms of Usele
pplappWeek Week 
he apOpen LOpen pli
tt ottt o6bb
ct tay [ADDRESS_89772]+3 days)+3 days)ot h eo heot h
ubjeNR5NRbjesuus
yn
eoeoeooeousalcccciarcerrrr
m
Xomcccc-c
XXa: edaaaakage.age.CCICCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89773] 2017
Appendix A Schedule of Study Procedures: Screening, Induction and Nonresponders (continued)
Study Procedure ScreeningInduction
Open Label Treatment 
PeriodInduction 
ObservationWeek 6 Nonresponders
Open Label Treatment Period
Days -28 to 
-1Week 0 (a)
Day 1Week 2
Day 15
(±2 days)Week 6a (b)
Day 43
(-5 days)Week 6b (b)
Day 43
(+3 days)Week 6b
Day 43
(+3 days)Pre-Week 14
Day 92
(+4 days)Week 14 (t)
Day 99
(±3 days)
OLE Nonenroller OLE Enroller
C l i n i c  V i s i t  N u m b e r [ZIP_CODE] NR5 PW14 NR6 NR6
Randomization X
Assess eligibility for OLE X
CDAI (k) X (k) X X (k) X(k) X (k) X (k)
PRO (IBDQ; EQ-5D) X X X X
PTE/AE assessment (l) X XXXX X X X
S A E  a s s e s s m e n t  ( m ) XXXXX X X X
Sample collection for:
Serum pregnancy test X X
Urine pregnancy test (n) X X X X X X
HBV, HCV, HIV screen X
FSH (o) X
Clinical chemistry X X X X X X
Hematology X (k) X X X (k) X X X (k)
Coagulation X
Urinalysis X X X X X
PK assessment (p) X X X X X
Fecal calprotectin (q) X X X X
CRP X X X X X
C. difficile stool sample (r) X
Property of eda: non-commercial use o nd subject to the applicable Terms of Usele
ued)ed)
pplicappWeek 6Week 
ea pOpen LaOpen Lalic
tto ttt o433
ect tdays)ays)o the ot hPo e
ot hoo
bjecNR5NR5ec
ubjebje
ds uub
d)d sdddsdXdndddd
Xooooeoseeeeusalrcrcrcrcrc
meXXmmXomcccc-c
XXon
XXno
XXa:
XXedCCI
CCI
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89774] 2017
Study Procedure ScreeningInduction
Open Label Treatment 
PeriodInduction 
ObservationWeek 6 Nonresponders
Open Label Treatment Period
Days -28 to 
-1Week 0 (a)
Day 1Week 2
Day 15
(±2 days)Week 6a (b)
Day 43
(-5 days)Week 6b (b)
Day 43
(+3 days)Week 6b
Day 43
(+3 days)Pre-Week 14
Day 92
(+4 days)Week 14 (t)
Day 99
(±3 days)
OLE Nonenroller OLE Enroller
C l i n i c  V i s i t  N u m b e r [ADDRESS_89775] table page.
Footnotes: 
Day=day after the first dose. HBV=hepatitis B virus, HCV=hep atitis C virus, NR=non-responders, OL=open-label, PML=progressive mul tifocal 
leukoencephalopathy, .
(a) All Baseline (Week 0) assessments will be done pre-dose.(b) Week 6a visit should be performed between Day 38 and 43 (in clusive) and Week 6b visit should be performed between Days 43 and 46 (inclusive). The Week 6a and 6b visits 
should not be performed on the same day.(c) Physical examination: Clin ically si gnificant findings will be recorded as concurrent conditions if they started prior to sign ing the informed consent, or as PTEs if they started after 
signing the informed consent and as AEs if they started after the first dose of study drug.(d) Vital signs: Height (cm) and weight (kg; without shoes) will be measured during screening. Weight and vital signs will also be measured on dosing days prior to dosing
(e) PML checklist: will be administered prior to each dosing event. The PML subjective checklist will be administered in person  at dosing occurring in the clinic during scheduled 
visits. The PML subjective checklist will be administered over the phone when the subject is injecting outside of the clinic.
(f) Diary review: will be administered prior to each dosing event either in person at dosing occurring in the clinic during sche duled visits or over the phone when the subject is 
injecting outside of the clinic.(g) Concomitant medications and procedures: Monitoring of concomitant medications and concomitant procedures will begin at sign ing of the informed consent.
(h)  
(i) TB screening: To be performed prior to dosing.
(j) Week 0 and 2 dosing will be done with vedolizumab IV; from randomization at Week 6B onwards dosing will be done with vedoli zumab SC. WK6 Nonresponders (NR) will 
receive a 3
rdinfusion with open-label vedolizumab IV and be assessed for response at WK14. Responders at Week 14 will be eligible for the OL E study, Week 14 Responders that do 
not enter the OLE study and Nonresponders at Week 14 will complete Visit NR6 and d iscontinue from the study.
(k) CDAI: CDAI score components are to be performed prior to dosing; the total CDAI score will be calculated once results are av ailable for all components. Hematocrit level from 
central laboratory results will be used for calculation of the CDAI score. The components of the CDAI score to determine eligibility at Week [ADDRESS_89776] be available w ithin 7 days prior to receiving the firs t dose of study drug (at a minimum, [ADDRESS_89777] 14 days prior to Week 0). For Randomization at Week 6b, the sample taken for the hematocrit at Week 6a will be used to calculate the CDAI score. For Week 14, the sample 
taken for hematocrit at pre-Week 14 will be used to calculate the CDAI score.(l) PTEs will be captured immediately following the signing of the informed consent at Screening, up until the first dose of st udy drug. Collection of AEs, to include concomitant le
cabplicaek 6 Nonk 6 No
pplicn Label TLabel ab
tot)o the apphe aPrePre-W
theD
o thpp
ththot ho 5oooooo
patitis C vititis C 
issititshouldshoul
nt conditioondi
y drugdrug.
during screring sc
L subjectsubjec iv
when the when th
rin personin pers
ncomitant m
mab IV; frob IV;
 IV and beV and 
Week [ADDRESS_89778] dose of study drug and will continue through Week 68/Final Safety Visit. To be performe d in person at dosing occurring in the clinic during 
scheduled visit. To be performed over the phone at dosing occurring outside of the clinic. (m) Collection of all SAEs will begin once the informed consent is signed and will continue through Week 68/ Final Safety Visit . To be performed in person at dosing occurring in the 
clinic during scheduled visit. (n) A urine pregnancy test will be completed for all female subjects of child bearing potential on a 4-weekly basis prior to admin istration of study drug.
(o) Follicle-stimulating hormone (FSH) level will be obtained for female subjects at Screening if they are postmenopausal by [CONTACT_82307] (ie, last regular menstrual cycle >1 years) and not 
surgically sterile. The FSH result must be >40 IU/L for the subject to be permitted not to use adequate contraception.(p) All PK  samples will be obtained at predose (within 30 minutes prior to dosing).(q) Fecal calprotectin stool sample should be collected from the first bowel movement on the day of collection.(r) A stool sample for culture, ova and parasite evaluation, and C. difficile assay will be obtained at Screening and at any time point during the study when a subject becomes 
symptomatic, including worsening or return of disease activity. (s)  
(t) For OLE enrollers, subjects should receive  their first OLE vedolizumab SC dose as close to Week 14 of MLN0002SC-3031 as poss ible (preferably within Week 14 ±3 days). If this 
window is too challenging for the sites, dosing within week 14 ±7 days is acceptable from a PK perspective (ie, maintaining tro ugh concentration at or above 10 μg/mL).
Property of [COMPANY_005]: For non-commercial use only andk d ect to the applicable Terms of Usele
rson at doson at d
o be perforbe perf
dministratinistrat
by [CONTACT_82308] d at anyat a
[ADDRESS_89779] 2017
Appendix A Schedule of Study Procedures (Maintenance Phase)
Study ProceduresMaintenance Phase (a) Final Safety 
Follow-up
Visit (b)Unscheduled 
Visit (c)46-Week Double Blind, Randomized Treatment Period 
(Week [ADDRESS_89780] occur +7 days after Randomization)
Wk 7 Wk 8Wk 
10, 12 
(d)Wk 
14Wk 
16, 
18, 20 
(d)Wk 
22Wk 
24, 
26, 28 
(d)Wk 
30Wk 
32, 
34, 36 
(d)Wk 
38Wk 
40, 
42, 44 
(d)Wk 
46Wk 
48 (d)Wk 
50Wk 
51Wk 
52/ET
(s) Wk 68
± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 7 
days ± 1 week
Clinic Visit Number 6 7 8 9 10 11 12 13 14 15 16
Physical examination (e) XXXXXX X X X
V i t a l  s i g n s  ( f ) X XXXXXXX X X X X
P M L  c h e c k l i s t  ( g ) XXXXXXXXXXXXX X X
PML wallet card X
D i a r y  r e v i e w  X XXXXXXX X X
Concomitant 
medications and 
proceduresXXXXXXXXXXXXXXX X X X
D o s i n g  - B l i n d e d  S C XXXXXXXXXXXXX
C D A I  ( h ) XXXXXX X  ( i ) X
PRO (IBDQ; EQ-5D) X X
12-lead ECG XX
PTE/AE assessment (k) X X XXXXXXXXXXXXX X X X
S A E  a s s e s s m e n t  ( l ) XXXXXXXXXXXXXXX X X X
Footnotes are on last table page.
Property of [COMPANY_005]: Fo mercial use only and subject to the applicable Terms of Usele
licpp
k k 
466Wk Wk
[ADDRESS_89781] tth
daysays± 3 ± 3
daydaeccc
ubjc
suuu
du
XXdddndXXannn
lyn
XX XlylyylyoneXXeeee
XXus
eral
X Xererercer
XXmeee
oXXFooo
a:o
XX Xa:a:a:eeda:CCI
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89782] 2017
Appendix A Schedule of Study Procedures (Maintenance Phase) (continued)
Study ProceduresMaintenance Phase (a)Final Safety 
Follow-up 
Visit (b)Unscheduled
Visit (c)46-week Double B lind, Randomized, Treatment Period
(Week [ADDRESS_89783] occur +7 days after Randomization)
Wk 7 Wk 8Wk 
10, 12 
(d)Wk 
14Wk 
16, 
18, 20 
(d)Wk 
22Wk 
24, 
26, 28 
(d)Wk 
30Wk 
32, 
34, 36 
(d)Wk 
38Wk 
40, 
42, 44 
(d)Wk 
46Wk 
48 (d)Wk 
50Wk 
51Wk 
52/ET
(s) Wk 68
± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 3 
days± 7 
days ± 1 week
Clinic Visit Number 6 7 8 9 10 11 12 13 14 15 16
Sample collection for:
Serum pregnancy test XX
Urine pregnancy test (m) wk10 X wk 18 X wk 26 X wk 34 X wk 42 X X
Clinical chemistry X X XXXX X X X ( r )
Hematology X X XXXX X  ( i ) X X ( r )
Coagulation X X
Urinalysis X
P K  a s s e s s m e n t  ( n ) X XXXXXXX X X X X
Fecal calprotect in(o) XX
CRP X X
C difficile stool sample (p) X (p)
Footnotes are on last table page.
Property of [COMPANY_005]: For n-co rcial use only and subject to the applicable Terms of Usele
licpp
Wk k 
4646WkW
48hehehe
tthe
3 3
daysays± 3 ±
dadecbjsudddddany wk 34k 34lyyy
oy
ooneoXXeeeeuslallll
Xrrrcir
oo-cn
rrrrCCI
CCI
Vedolizumab SC
Study No. MLN0002SC-[ADDRESS_89784] 2017
Footnotes: 
Day=day after the first dose in Induction Period.  HBV=hepatitis B virus, HCV=hepatitis C virus, PML=progressive multifocal leukoencephalopathy(a) Maintenance period: There should be a minimum of 7 days between 2 consecutive doses.(b) Subjects discontinued from the study for any reason during the Maintenance Phase will complete the ET Visit, the Final Safety  Visit and LTFU. These subjects are not enrolling 
in the OLE study.
(c) Subjects seen at an unscheduled visit for disease exacerbation or SAE will complete the Unscheduled Visit assessments.(d) Nonclinic visits. Subject will inject once the site has confirmed the subject can inject via the pre-dose phone call.(e) Physical examination: Clinically significan t findings will be recorded as AEs if they start after the first dose of study drug .
(f) Vital signs: Weight and vital signs will also be measured on dosing days prior to dosing.(g) PML checklist: will be administered prior to each dosing event. The PML subjective checklist will be administered in person  at dosing occurring in the clinic during scheduled 
visits. The PML subjective checklist will be administered over the phone when the subject is injecting outside of the clinic.(h) CDAI score components are to be performed prior to dosing; the total CDAI score will be calculated once results are availabl e for all components. 
(i) Hematocrit level from central laboratory results will be used for calculation of the CDAI score.
(j)  
(k) Collection of AEs, to include concomitant medications, will begin following first dose of study drug and will continue thro ugh Week 68/Final Safety Visit. To be performed in 
person at dosing occurring in the clinic during scheduled visit. To be performed over the phone at dosing occurring outside of the clinic. 
(l) Collection of all SAEs will continue from Week 7 through Week 68/Final Safety Visit. To be performed in person at dosing oc curring in the clinic during scheduled visit. To be 
performed over the phone at dosing occurring outside of the clinic.(m) A urine pregnancy test will be completed for all female subjects of child bearing potential on a 4-weekly basis prior to admin istration of study drug.
(n) PK samples at Weeks 7, 51 and 52 can be collected at any time during the visit. All other PK  samples will be obtained at pr edose (within 30 minutes prior to dosing). The 
(o) Fecal calprotectin stool sample should be the first bowel movement on the day of collection.
(p) A stool sample for culture, ova and parasite evaluation, and C. difficile assay will be obtained (if indicated) at any time point during the study when a subject becomes 
symptomatic, including worsening or return of disease activity.(q)  
(r) If indicated.
(s) Subjects randomized in the Maintenance Phase who complete the study or ET after Week 6 for disease worsening or after Week 14 wh o require rescue medication will be offered 
entry into the OLE study after completion of the Week 52/ET assessments. Week [ADDRESS_89785] dose of study drug for 
completers/ET. 
Property of [COMPANY_005]: For non- er use only  subject to the applicable Terms of Usele
, PML=prPML=p
Safety Visety Vi
ments.nts.
l.
of study drstudy d
dministeredminist
utside of thide of 
ted once rd once
e of study dof stu
he phone aphone a
Visit. To it. T
earing potaring p
e visit. All A
nt on the don
difficileficile as
ho compleo com
Week 52Week 52 /ECCI
CCI
CCI
CCICCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89786] igators from 
the FDA are summarized in the “Statement of Investigator” (Form FDA 1572) which must 
be co mpleted and signed before the Invest igator may participate in this study . 
The invest igator agrees to assume the fo llowing responsibilit ies:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
study  related duti es and funct ions, the i nvest igator/inst itution shoul d ensure that this 
individual or party is qualified to perform those study related duties and funct ions,and 
shoul d implement procedures to ensure the integrity  of the study  related duti es and 
funct ions performed and any data generated.
4.Ensure that study related procedures, including study specific (nonroutine/nonstandard 
panel) screening assessments are NOT performed on potential subjects, prior to the 
recei pt of written approval  from relevant governing bodies/authorities.
5.Ensu re that all co lleagues and emplo yees assist ing in the conduct of the study are 
inform ed of these obligat ions.
6.Secure prior approval of the study  and any  changes by  [CONTACT_82309]/IEC that 
conform to 21 Code of Federal Regulat ions (CFR) Part 56, ICH, an d local regul atory  
requi rements.
7.Ensure that the IRB/IEC will be responsible for initial review, continuing review, and 
approval  of the protocol . Prom ptly report to the IRB/IEC all changes in research 
activit y and all ant icipated risks to subjects. Make at least yearly reports on the progress 
of the study  to the IRB/IEC, and issue a final report within [ADDRESS_89787]’s medical chart. Valid informed consent is 
the mo st current version approved by [CONTACT_1201]/IEC. Each informed consent form should 
contain a subje ct auth orization secti on that describes the uses and disclosures of a 
subject’s personal informat ion (including personal healt h informat ion) that will take 
place in connect ion with the study. If an informed consent form does not include such a 
subject auth orization, then the investigator must obtain a separate subject authorizatio n 
form from each subject or the subject’s legally acceptable representative.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89788] 2017
10.Prepare and maintain adequate case histories of all persons entered into the study , 
including (e)CRFs, hospi [INVESTIGATOR_1097], laboratory results, etc, and maintain these data for 
a minimum o f 2years fo llowing notification by [CONTACT_82310]. The in vestigator should contact [CONTACT_4182] m the 
sponsor before disposing of any  such documents.
11.Allow possible inspection and copying by [CONTACT_4216] -specified 
essent ial docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of 
sponsor -supplied drugs, and return all unused sponsor- supplied drugs to the sponsor.
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the 
sponsor within 24 hours.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89789]:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of th e subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to 
each treatment.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, 
when applicable, to an embryo, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be 
expected from the researc h. When there is no intended clinical benefit to the subject, 
the subject should be made aware of this.
13.Disclosures of appropri ate al ternat ive procedures or courses of treatment, if any, that 
might be advantageous to the subject and their important potenti al risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the 
subject will be maintained, and a note of the possibilit y that regul atory  agencies, 
auditor(s), IRB/IEC, and the monitor may inspect the records. B y signing a wri tten 
inform ed consent form , the subject or the subject’s legally acceptable representative is 
authori zing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any  
compensat ion and an explanat ion as to whet her any medical treatments are available if 
injury  occurs and, if so, what they  consist of or where further informat ion may be 
obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, i f any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact [CONTACT_82311] (invest igator), subject’s rights, and IRB/IEC and whom to contact [CONTACT_82312] a research -related injury  to the subject.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002S C-[ADDRESS_89790]’s decisio n to withdraw from the research and 
procedures for orderly termination of participation by [CONTACT_423].
21. A statement that the subject or the subject’s legally acceptable representative will be 
informed in a timely manner if information becomes available that may be relevant to 
the subject’s willingness to continue participation in the study.
22. A statement that results of analysis will not be disclosed to an 
individual, unless prevailing laws require the sponsor to do so.
23. The foreseeable circumstances or reasons under which the subject’s participation in the 
study may be terminated.
24. A written subject authorization (either con tained within the informed consent form or 
provided as a separate document) describing to the subject the contemplated and 
permissible uses and disclosures of the subject’s personal information (including 
personal health information) for purposes of conducting the study. The subject 
authorization must contain the following statements regarding the uses and disclosures 
of the subject’s personal information:
a) that personal information (including personal health information) may be 
processed by [CONTACT_82313], including, without limitation, to the following: 
(1) [COMPANY_005], its affiliates, and licensing partners; (2) business partners assisting 
[COMPANY_005], its affiliates, and licensing partners; (3) regulatory agencies and other 
health au thorities; and (4) IRBs/IECs;
b) it is possible that personal information (including personal health information) may 
be processed and transferred to countries that do not have data protection laws that 
offer subjects the same level of protection as the data protection laws within this 
country; however, [COMPANY_005] will make every effort to keep your personal information 
confidential, and your name [CONTACT_82322] [CONTACT_2371];
c) that personal information (including personal health information) may be added to 
[COMPANY_005]’s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of 
the safety and effectiveness of the study medication(s), studying other therapi[INVESTIGATOR_82256], developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency 
of future clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal 
information (including personal health informatio n) upon withdrawal from the will be will be
relevanteleva
sclossclos ed e
bject’s pect’s 
n the inthe in
subject ubjec
s personaperson
conductionduc
tatementatemen
uding perding p
o other p othe
oses, inces, in
s, and lic, and l
s, and licand l
; and (4)and (4
that pershat p
sed and td and
ubjects thubjects 
ntry; howy; ho
onfidentnfide
by [CONTACT_82314]
c)c)thtCCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89791] the scient ific integrity of the research; and
e)that the subject’s ident ity will remain confident ial in the event that study results are 
published.
25.Female subjects of childbearing potentia l (eg, nonsterilized, premenopausal female 
subjects) who are sexually act ive must use adequate contraception (as defined in the 
inform ed consent) from  Screening throughout the duration of the study . Regular 
pregnancy tests will be performed throughout the study  for all female subjects of 
childbearing potential. If a subject is found to be pregnant during study , study  
medicat ion will be discont inued and the invest igator will offer the subject the choice to 
receive unblinded treatment informat ion.
26.Male subjec ts must use adequate contraception (as defined in the informed consent) 
from Screening throughout the duration of the study . If the partner or wife of the 
subject is found to be pregnant during the study , the invest igator will o ffer the subject 
the cho ice to receive unblinded treatment informatio n.
27.A statement that clinical trial informat ion from this trial will be publicly disclo sed in a 
publicly  accessible website, such as ClinicalTrials.gov.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89792] igator, including his or her 
name, address, and other personally ident ifiable informat ion. In addit ion, investigator’s 
personal informat ion may be transferred to other parties located in countries throughout the 
world (eg, the United Kingdo m, [LOCATION_002], and Japan), including the following:
[COMPANY_005], its affiliates, and licensing partners.
Business partners assist ing [COMPANY_005], its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by [CONTACT_4217]:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and s ubmissio n of regulatory filings, correspondence, and communications 
to regulatory  agencies relat ing to the study.
Preparati on and submissio n of regulatory filings, correspondence, and communications 
to regulatory  agencies relat ing to other medicat ions used in other clinical studies that 
may contain the same chemical co mpound present in the study medicat ion.
Inspect ions and invest igations by [CONTACT_4218].
Self-inspect ion and internal audit within [COMPANY_005], its affiliates, and li censing partners.
Archiving and audit of study  records.
Posting investigator site contact [CONTACT_4203], study details and results on publicly 
accessible clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferr ed to other countries that do not have 
data protecti on laws that offer the same level of protection as data protection laws in 
investigator’s own country .
Invest igator acknowledges and consents to the use of his or her personal information by 
[CONTACT_82315].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002S C-[ADDRESS_89793] 2017
Appendix FCrohn’s Disease Activity Index (CDAI)
Category CountInitial 
TotalMultiplicati on 
Factor Total
Number of liquid or very 
soft stools7-day total number of liquid or very 
soft stools (reported on the 7 days 
immediately prior to the study visit)2
Abdominal pain 7-day total of daily abdominal pain 
scores on a 3 -point scale: 0 = no ne, 
1=mild, 2=moderate, 3=severe 
(reported on the 7 days immediately 
prior to the study visit)5
General well being 7-day total of daily general well -being 
scores on a 4 -point scale: 0=generally 
well, 1=slightly under par, 2=poor, 
3=very poor, 4=terri ble (reported on 
the 7 day s immediately  prior to the 
study visit)7
Extra -intestinal 
manifestations of Crohn’s 
Disease Total number of checked boxes (check 
allthat apply):
Arthritis/arthralgia
Iritis/uveitis
Erythema nodosum/pyoderma 
gangrenosum/ aphthous stomatitis
Anal fissure, fistula, or abscess
Other fistula
Fever over 37.8°C during past 
week20
Lom otil/Imodium/opi[INVESTIGATOR_39760] = 1
No = 030
Abdominal mass None = 0
Questionable = 2
Definite = 510
Hematocrit (%) (a) Males: subtract value from 47
Females: subtract value from 426
Body Weight (b) (1 –(Body weight/
Standard Weight)) 100 1
Final Score Add totals:
Source: Adapted from: Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn’s disease 
activity  index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70 (3):439 -44.
(a) If hematocrit subtotal <0, enter 0.
(b) If body weight subtotal < -10, enter -10.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002S C-[ADDRESS_89794] 2017
Appendix H Detailed Description of Amendments to Text
The primary section(s) of the protocol affected by [CONTACT_39835]. 06 are 
indicated. The corresponding text has been revised throughout the protocol. 
Change 1:Clarification of the Sponsor address in Japan.
The primary change occurs on Page 1: 
Initial 
wording:[COMPANY_005] Development Center Japan, 
[COMPANY_005] Pharmaceutical Company Limited, 
1-1, Doshomachi 4-Chome, Chuo-ku Osaka 540-8645, Japan
Amended or new 
wording:[COMPANY_005] Development Center Japan, 
[COMPANY_005] Pharmaceutical Company Limited, 
1-1, Doshomachi 4-Chome, Chuo-ku Osaka 540-8645, Japan
Rationale for Change:
Administrative change to the Sponsor address in Japan. 
Section  3.4 Corporate Identification also contains this change. 
Change  2:Administrative change to the Responsible Medical Officer and Approvers.
The primary change occurs in Section  1.1 Contacts and Section  1.2 Approval:
Initial 
wording:
Amended or new 
wording:
Initial wording:
Amended or new 
wording:
Initial wording:
Property of Takemended mende
or newor new
wordwokeng:g:
ke
yse only and subject to the applicable Terms of Useble
ica
45, Japa45, Japthe
n. bje
this chathis chan
ponsiblensibnly
ContaConte
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Vedolizumab SC
Study No. MLN0002S C-[ADDRESS_89795] 2017
Amended 
or new 
wording:
Rationale for Change:
Administrative change to study personnel.
Change  3:Inclusion of an additional secondary objective and endpoint, and exploratory 
endpoint.
The primary change occurs in Sections  5.1.2 Sec ondary Objectives, 5.2.2 Secondary 
Endpoints and 5.2.4 Exploratory Endpoints:  
Added 
text:!To assess the effect of vedolizumab SC maintenance treatment on 
clinical remission at Week 52, in subjects who are naïve to TNF- α 
antagonist exposure and achieved clinical response at Week 6 
following administration of vedolizumab IV at Weeks 0 and 2.
Added 
text:!Proportion of TNF- α antagonist naïve subjects who achieved clinical 
remission, defined as CDAI score ≤150, at Week 52.
Added 
text:
Rationale for Change:
Inclusion of an additional secondary objective and associated endpoints to assess the effect
of vedolizumab SC treatment in subjects with no prior TNF- α antagonist exposure, TNF- α 
exposure, and TNF- α failure. 
Section  2.0 STUDY SUMMARY also contains this change. 
Change  4: Clarification to the Fi nal Visit/Early Termination procedures for subjects who 
complete (OLE Enroller/Nonenroller) at Week 14 (Induction Phase), and subjects who 
complete (Week 52) or discontinue from the Maintenance Phase.
The primary change occurs in Section  6.1 Study Design and Appendix A Schedule of 
Study Procedures: Screening, Induction and Nonresponders:
Property of [COMPANY_005]primaryrimary cy
udyudyProcProyyda: For non-commercia  and subject to the applicable Terms of Useoratoryoratoryab
Secondaecondapp
nce treance tr
o are naïare n
responseespon
b IV at WIV at Wot
ïve subjee sub
≤150, a150,ds
ndary obdary o
nt in subjin sub
urere. . a
SUMMAUMc
ificaticatioion
LE EnroE Enr
(Week 5Weekno
da
fT[COMPANY_003]
CCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89796] 2017
Initial 
wording: Subjects who achieve a clinical response at Week 6 will be rando mized 
into the Maintenance Phase. Upon complet ion of the Week 52 assessment 
or upon early discont inuat ion due to treatment failure (ie, disease worsening 
or need for rescue medicat ions) these subjects will be eligible to ent er the 
OLE study . 
 Subjects who do not achieve a clinical response at Week [ADDRESS_89797] 
infusio n of vedo lizumab IV 300 mg at Week 6. Subjects who achieve a 
clinical response at Week 14 (by [CONTACT_82274]) will be eligible to enroll in the OLE 
study , while subjects who do not achieve clinical response will be 
discontinued. 
…
Subjects who do not participate in the OLE trial or are discontinued, will enter 
the Follow -Up Peri od and com plete a fina l on-study  safety  assessment at 
18weeks (ie, 5 vedolizumab half -lives) from the last study drug dose (Week 50 
or early terminat ion [ET]). 
Addit ionally , subjects who do not participate in the OLE trial will be required to 
participate in a long -term follow-up (LTFU) safet y survey by [CONTACT_756], [ADDRESS_89798] dose of study  drug.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89799] 2017
Amended 
or new 
wording: Subjects who achieve a clinical response at Week 6 will be rando mized 
into the Maintenance Phase. Upon complet ion of the Week 52 assessment 
or upon early discont inuation due to treatm ent failure (ie, disease worsening 
after Week 6 or need for rescue medicat ions after Week 14 ) these subjects 
will be eligible to enter the OLE study  (Table 7.a). 
 Subjects who do not achieve a clinical response at Week [ADDRESS_89800] 
infusio n of vedo lizumab IV 300 mg at Week 6. Subjects who achieve a 
clinical response at Week 14 (by  [CONTACT_82316] o score) will be eligible to 
enroll in the OLE study . Subje cts who respond but choose not to enroll 
in the OLE study and ,while subjects who do not achieve clinical response 
at Week 14will be discont inued. 
…
Subjects who do not participate in the OLE trialstudy or are discont inued from 
the study before Week 6 , will enter the Follow -Up Period and complete a final 
on-study  safet y assessment at 18 weeks (ie, 5 vedolizumab half -lives) from the 
last study  drug dose (Week 50 or early terminat ion [ET]) .
Addit ionally , subjects who do not parti cipate in the OLE trialstudy or have 
discontinued before Week 6 will be required to participate in a long -term 
follow-up (LTFU) safet y survey  by [CONTACT_82317], [ADDRESS_89801] dose of 
study  drug.
Appendix ASchedule o f Study  Procedure s: Screening, Induction and Nonr esponders :
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002S C-[ADDRESS_89802] 2017
Description 
of change:Column labelled Week 14, Day 99 (±3 days) split into 2 columns labelled OLE 
nonenroller and OLE enroller :
!Footnote (t) added:
o(t) For OLE enrollers, subjects should receive their first 
OLE vedolizumab SC dose as close to Week 14 of 
MLN0002SC-3031 as possible (preferably within Week 14 
±3 days). If this window is too challenging for the sites, 
dosing within week 14 ±7 days is acceptable from a PK 
perspective (ie, maintaining trough concentration at or 
above 10 μg/mL).
!OLE nonenroller column:
oX included in rows Physical examination, Vital signs, PML 
checklist, Diary review, Concomitant medications and 
procedures,  CDAI, PTE/AE 
assessment, SAE assessment, Urine pregnancy test , PK 
assessment 
!OLE enroller column:
oX included in rows Physical examination, Vital signs, PML 
checklist, Diary review, Concomitant medications and 
procedures, Fistula Assessment (if indicated), Assess eligibility 
for OLE, CDAI, PRO (IBDQ; EQ-5D), , PTE/AE assessment, SAE assessment, and Urine pregnancy test .
Rationale for Change:
Clarification to the Final Visit/Early Termination procedures for subjects who complete 
(OLE Enroller/Nonenroller) at Week 14 in the Induction Phase, and subjects who complete 
(Week 52) or ET from the Maintenance Phase.
The following sections also contain this change:
! Figure 6.a Schematic of Study Design.
! Section  7.[ADDRESS_89803].
! Section  [IP_ADDRESS] Nonr esponders.
! Section  9.3.3 Final Visit or ET.
! Section  9.3.4 Final Safety Follow-up Visit.
Property of [COMPANY_005]: For g sectg sect ioi
ure re6.a6.aSc
SectiSecti ono
SectSec
!!r non-commeal Visit/EVisit/
nrooller) ller)mercial use only ect to the applicable Terms of Useek [ADDRESS_89804] 2017
Change  5:Clarification to the study design schematic.
The primary change occurs in  Figure 6.a Schematic of Study Design:
Initial 
wording:(c) Visit 1 of Extension Study MLN0002SC-3030 is within 1 week of 
completing Week 52 (Visit 15) procedures. Subjects not randomized into the 
Maintenance Phase (Week 6 Nonresponders) and respond at Week 14 on 
vedolizumab IV 300 mg are also eligible for entry into the Extension Study.
Amended or new 
wording:(c) Visit [ADDRESS_89805] dose of study drug for Week 52 completers/ET or 1 week 
of Week 14 for Week 14 responders of completing Week 52 (Visit 15) 
procedures. Maintenance Phase (Week 6 Nonresponders) and respond at Week 
14 on vedolizumab IV 300 mg are also eligible for entry into the Extension 
Study.
Rationale for Change:
Clarification to the timing of the first visit of OLE Study MLN0002SC-3030.
Change  6:Study design updated to clarify that all endoscopi[INVESTIGATOR_82257].
The primary change occurs in Section  6.1 Study Design:
Initial 
wording: 
 
 
 
Propese onlydyyly and subject to the applicable Terms of Usetudyudy.
s withinwithi
ET or 1 T or 1 
2 (Visit 2 (Visithe and respnd resth
y into thy into tolic
dyMLN0MLNybje
endoscondosnd
DesigDesiyyly
eoCCI
CCI
Vedolizumab SC
Study No. MLN0002S C-[ADDRESS_89806] 2017
Rationale for Change:
Study design updated to clarify that all endoscopi[INVESTIGATOR_82257].
The following sections also contain this change:
!
! Appendix A Schedule of St udy Procedures: Screening, Induction and Nonresponders
Change  7:Clarification to Inclusion Criterion #11.
The primary change occurs in Section  7.1 Inclusion Criteria:
Initial 
wording:!Corticosteroids
i. The subject has signs and symptoms of persistently active disease 
despi[INVESTIGATOR_040] a history of a least one 4-week induction regimen that 
included at dose equivalent to prednisone ≥[ADDRESS_89807] has a history of intolerance of corticosteroids (including, but not limited to, Cushing’s syndrome, 
osteopenia/osteoporosis, hyperglycemia, insomnia, and infection).
Amended 
or new 
wording:!Corticosteroids
i. The subject has signs and symptoms of persistently active disease 
despi[INVESTIGATOR_040] a history of a least one 4-week induction regimen that 
included at dose equivalent to prednisone ≥[ADDRESS_89808] has a history of intolerance of corticosteroids 
(including, but not limited to, Cushing’s syndrome, 
osteopenia/osteoporosis, hyperglycemia, insomnia, and infection).
iv. The subject had a relapse within 3 months of stoppi[INVESTIGATOR_82243]. Property of [COMPANY_005]: For non-commteroieroidsd
The subjThe sub
despi[INVESTIGATOR_82258] ≥30≥[ADDRESS_89809]
but not lut not
a/osteoposteohe
mCCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89810] 2017
Rationale for Change:
Clarificat ion to the inclusion criterion to include subjects who have relapsed within 
3months of stoppi[INVESTIGATOR_82259] E uropean Crohn’s and Colitis 
Organizat ionguidelines .
Change 8:Clarificat ion to Excl usion Criterion #5.
The primary  change occurs in Section 7.2.[ADDRESS_89811] inal Exclusio n Cri teria:
Initial 
wording:5. The subject has had ileostomy, colostomy , or known fixed symptom atic 
stenosi s of the intest ine.
Amended 
or new 
wording:5. The subject has hadileostomy, colostomy, or known fixed symptomat ic 
stenosi s of the intest ine.
Rationale for Change:
Subjects with past medical history  but no current ileostomy , colostomy , or known fixed 
symptom atic stenosis of the intestine are allowed into the study .
Change 9:Clarificat ion to Excl usion Criterion #15.
The primary  change occurs in Section 7.2.3 General Exclusio n Cri teria:
Initial 
wording:15. The subject has chronic hepat itis B virus (HBV) infect ion* or chronic 
hepat itis C virus (HCV) infect ion.
* HBV immune subjects (ie, being hepat itis B surface ant igen [HBsAg] 
negat ive and hepat itis B ant ibody positive) m ay, however, be included.
Amended 
or new 
wording:15. The subject has chronic hepat itis B virus (HBV) infect ion* or chronic 
hepat itis C virus (HCV) infect ion.
* HBV immune subjects (ie, being hepat itis B surface ant igen [HBsAg] 
negat ive and he patitis B surface antibody  [HBsAb] posit ive) may, 
however, be included.
Rationale for Change:
Clarificat ion to Exclusion criterion text.
Change 10:Clarificat ion to Excl usion Criterion #20.
The primary  change occurs in Section 7.2.3 General Exclusio n Cri teria:
Initial 
wording:20. The subject has had previous exposure to approved or invest igational 
anti-integrins (eg, natalizumab, efalizumab, etrolizumab, AMG 181), 
anti-MAdCAM -1 ant ibodies, or rituximab.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89812] 2017
Amended 
or new 
wording:20. The subject has had previous exposure to approved or invest igational 
anti-integrin santibodies (eg,natalizumab, efalizumab, etrolizumab, AMG 
181), anti -MAdCAM -1 ant ibodies, or rituximab.
Rationale for Change:
Clarificat ion to Exclusion criterion text.
Change 11:Clarificat ion to the period for excluded medicat ions and treatments.
The primary  change occurs in Section 7.3Excluded Medicat ions and Treatments :
Initial 
wording:The fo llowing m edicat ions are excluded fro m use during the study : 
Amended 
or new 
wording:The fo llowing m edicat ions are excluded fro m use during the study  (from 
informed consent to Week 68) : 
Rationale for Change:
Inclusio n to text to outline the specific perio d for excluded medicat ions and treatments.
Change 12:Clarificat ion to Secti on 9.1.5 Vital Signs Proc edure.
The primary  change occurs in Section 9.1.5 Vital Sign Procedure :
Deleted 
text:When vital signs are scheduled at the same t ime as blood draws, the blood draw 
will take priorit y and vital signs will be obtained wit hin 0.5 hour b efore the 
scheduled blood draw. 
Rationale for Change:
There i s no time restriction between the timing of the vital sign measurements and blood 
draws during the same visit.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

Vedolizumab SC
Study No. MLN0002S C-[ADDRESS_89813] 2017
Change  13:Clarification to Section [IP_ADDRESS] Diary Completion and Review.
The primary change occurs in Section  [IP_ADDRESS] Diary Completion and Review:
Initial 
wording:Diary entries will be made daily by [CONTACT_82291], and 
will be used for CDAI calculation. At screening, subjects will be instructed on 
how to appropriately complete the daily diar y. The symptoms of CD must be 
recorded throughout the study, including the Screening Period. Diary entries will be made daily by [CONTACT_36090] a validated electronic system. At each 
visit, including during screening, the CDAI score must be calculated prior to 
dosing by [CONTACT_82318] e based on daily diaries, laboratory 
assessments, and clinical examination and recorded in the subject’s source 
documents. 
The CDAI score evaluated during screening will be used to determine 
eligibility, using subject diary entries within 14 days prior to Week 0.  
Amended 
or new 
wording:Diary entries will be made daily by [CONTACT_82291], and 
will be used for CDAI calculation. At screening, subjects will be instructed on 
how to appropriately complete the daily d iary. The symptoms of CD must be 
recorded throughout the study, including the Screening Period. Diary entries 
will be made daily by [CONTACT_36090] a validated electronic system. At each 
visit, including during screening, the CDAI score must be calculated prior to 
dosing by [CONTACT_941] , accessed by [CONTACT_82319], laboratory assessments, and clinical 
examination and recorded in the subject’s source documents. 
The CDAI score evaluated during screening will be used to determine 
eligibility, using subject diary entries within [ADDRESS_89814] 14 days prior to Week 0. 
 
 
 
Property of [COMPANY_005]: For non-co rcial use ony subjectsubje
on. At sn. At 
ete the dae the 
studytudy, inc, in
he subjee subj
ng screecre
d on daion 
n and reand r
DAI scorAI sco
ibilitbility,u
minimuminimu
be reqbe re
comcon ubject to the applicable Terms of Usen 
be be 
triies es 
m. At eacm. At e
ted priord pri
aboratoryborator
ubject’s bject’
used to ded to 
ys prior ys prio
nCC
I
CCICCI
Vedolizumab SC
Study No. MLN0002S C-[ADDRESS_89815] 2017
Rationale for Change:
Clarification to text that the CDAI scor e is automatically calculated by [CONTACT_82320]. Clarification to the number of days of diary 
data that is required for the CDAI calculation at Screening.
Appendix A Schedule of St udy Procedures: Screening, Induction and Nonresponders also 
contains this change. 
Change 14: ECG procedure updated.
The primary change occurs in S ection  9.1.12 ECG Procedure:
Initial 
wording:Subjects will be supi[INVESTIGATOR_82260] [ADDRESS_89816] identifiers will be removed or 
obscured.
Amended or new 
wording:Subjects will be supi[INVESTIGATOR_82260] [ADDRESS_89817] identifiers will be removed or 
obscured.
Rationale for Change:
ECG tracings are source documentation and will not be seen by [CONTACT_456].
Change  15:Addition of a Pre–Week [ADDRESS_89818] udy Procedures: Screening, 
Induction and Nonresponders:
Description of change:Additional column labelled Pre-Week 14, Day 92 (+4 days)
!X included for Serum pregnancy test , Clinical chemistry , 
Hematology , Urinalysis , PK assessment , Fecal 
Calprotectin and CRP .
Rationale for Change:
Additional visit so that the safety laboratory samples can be taken so that the results are 
current and available for the Week 14 visit for Week 6 nonresponders. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Uselso so 
ica
app
minutesminute
and initand in i
 will bewill bhe
for [ADDRESS_89819] ideaub
n and win and won
eek 14 vek 14 al 
AppendAppen
erss::er
al colcolumullll
X incX in
HeHco
ale for Cle for
dittioional nal
current acurrenta:a:a:
of CCI
Vedolizumab SC
Study No. MLN0002SC -[ADDRESS_89820] 2017
Change 16:Update to Appendix ASchedule of Study  Procedures f or Crohn’s 
disease –related events.
The primary  change occurs in Appendix ASchedule of Study  Procedure s: Screening, 
Induct ion and Nonr esponders :
Descript ion 
of change:Row l abelled CD-related events removed.
Rationale for Change:
CD-related events removed from the Induct ion Phase and Maintenance Phase schedules as 
these are recorded as AEs, SAEs, or concomitant procedures in the eCRF. 
Change 17:Update to Appendix BResponsibilit ies of the Invest igator.
The primary  change occurs in Section Appendix BResponsibilit ies of the Invest igator : 
Added 
text:3. If the investigator/institution retains the services of any individual or 
party to perform study related duties and functions, the 
investigator/institution should ensure that this individual or party is 
qualified to perform those study related duties and functions, and 
should implement procedures to ensure the integrity of the study 
related duties and functions performed and any data generated.
Rationale for Change:
Upda te to the Responsibilit ies of the Investigator in line with Section 4.2.[ADDRESS_89821] ice E6 (R2), which was revised on 01 December 2016.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  

  


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GDIF䣒䣴䣱䣶䣱䣥䣱䣮䢢䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢸䢢䣃䢢䣒䣪䣣䣵䣧䢢䢵䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢮䢢䣒䣮䣣䣥䣧䣤 䣱䢯䣅䣱䣰䣶䣴䣱䣮䣮䣧䣦䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧䢢䣇䣨䣨䣫䣥䣣䣥䣻
䣣䣰䣦䢢䣕䣣䣨䣧䣶䣻䢢䣱䣨䢢䣘䣧䣦䣱䣮䣫䣼䣷䣯䣣䣤䢢䣕䣷䣤䣥䣷䣶䣣䣰䣧䣱䣷䣵䢢䣣䣵䢢䣏䣣䣫䣰䣶䣧䣰䣣䣰䣥䣧䢢䣖䣪䣧䣴䣣䣲䣻䢢䣫 䣰䢢䣕䣷䣤䣬䣧䣥䣶䣵䢢䣙䣫䣶䣪䢢䣏䣱䣦䣧䣴䣣䣶䣧䣮䣻䢢䣶䣱䢢䣕䣧䣸䣧䣴䣧䣮䣻
䣃䣥䣶䣫䣸䣧䢢䣅䣴䣱䣪䣰䯑䣵䢢䣆䣫䣵䣧䣣䣵䣧䢢䣙䣪䣱䢢䣃䣥䣪䣫䣧䣸䣧䣦䢢䣅䣮䣫䣰䣫䣥䣣䣮䢢䣔䣧䣵䣲䣱䣰䣵䣧䢢䣈䣱䣮䣮䣱䣹䣫䣰䣩 䢢䣑䣲䣧䣰䢯䣎䣣䣤䣧䣮䢢䣘䣧䣦䣱䣮䣫䣼䣷䣯䣣䣤䢢䣋䣰䣶䣴䣣䣸䣧䣰䣱䣷䣵
䣖䣪䣧䣴䣣䣲䣻
%LRVWDWLVWLFV$SSURYDO $XJ87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO $XJ87&
&OLQLFDO6FLHQFH$SSURYDO $XJ87&
&OLQLFDO$SSURYDO $XJ87&
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Useble Tate ate 
ablHH:mm ‘UH:mm eT
ab87&87&

$XJ$XJ
$X$[COMPANY_003]